

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Risk factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Mainland China.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016280
Article Type:	Research
Date Submitted by the Author:	08-Feb-2017
Complete List of Authors:	Liu, Yan; Peking University Third Hospital, Department of Ophthalmology Yang, Jiarui; Peking University Third Hospital, Department of Ophthalmology Tao, Liyuan; Peking University Third Hospital, Research Center of Clinical Epidemiology Lv, Hui bin; Peking University Third Hospital, Department of Ophthalmology Jiang, Xiaodan; Peking University Third Hospital, Department of Ophthalmology Zhang, Mingzhou; Peking University Third Hospital, Department of Ophthalmology Li, Xuemin; Peking University Third Hospital, Department of Ophthalmology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Medical management
Keywords:	Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, risk factor, blood glucose, WHR, BMI

SCHOLARONE™
Manuscripts

1
2
3
4 Title: Risk factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in
5
6 Mainland China.

7
8
9 Running title: Risk factors of DR in China

10
11 Authors: Yan Liu MD^{1*}, Jiarui Yang MD^{1*}, Liyuan Tao PhD², Huibin Lv MD¹, Xiaodan
12
13 Jiang MD¹, Mingzhou Zhang MD¹, Xuemin Li MD¹

14
15
16 * These authors contributed equally to this work.

17
18
19 1 Department of Ophthalmology, Peking University Third Hospital

20
21 2 Research Center of Clinical Epidemiology, Peking University Third Hospital

22
23
24 Corresponding author: Xuemin Li MD

25
26 Address: Department of Ophthalmology, Peking University Third Hospital, No.49

27
28
29 Huayuan North Street, Haidian District, Beijing, China

30
31 Email: 13911254862@163.com; lxm1xm66@sina.com.cn

32
33
34 Word count: 3448 words

35
36
37 Number of figures: 2.

38
39
40 Number of tables: 3.

Risk factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in

Mainland China

Abstract:

Objectives: To explore the risk factors of diabetic retinopathy (DR) and sight threatened diabetic retinopathy (STDR) among Chinese patients with diabetes.

Design, setting and participants: A cross-sectional investigation was performed in eight screening clinics in six provinces across mainland China. Information of risk factors was recorded in screening clinics, and in these risk factors, sex, age, diagnosis age, diabetes duration, SBP, DBP, FBG, HbA1c were recorded in each clinic while others were partially collected. Relationship between risk factors and DR, STDR was explored in both eight factors mentioned above and all factors.

Main outcomes and measures: Risk factors of DR and STDR, and a nomogram of the results.

Results: Younger age, longer diabetes duration, higher SBP, higher FBG, and higher HbA1c were independent risk factors for both DR and STDR in eight-factor analyses. In all-factor analysis, younger age, longer diabetes duration, higher SBP, oral medicine, and insulin use were independent risk factors for both DR and STDR, while higher PBG, HbA1c, triglyceride and LDL were independent risk factors only for DR, and higher FBG only for STDR.

Conclusions: In this cross-sectional investigation, several risk factors were found for DR and STDR. What's worth to mention is that FBG, PBG and HbAc were all risk factors for DR or STDR, which implied that a stricter blood glucose control for clinical

1
2
3
4 practice was required.
5

6 **Key words:** diabetic retinopathy, risk factor, glucose, WHR, BMI
7
8
9

10
11 **Strength and limitations of this study**

- 12 ● This is a cross-sectional population-based (13473 subjects) estimate of the risk
13 factors of diabetic retinopathy
- 14 ● The study was performed in eight hospitals from 6 different provinces in mainland
15 China, and participants were from hospitals and communities which included
16 rural and urban regions.
- 17 ● We separately analyzed the risk factors for diabetic retinopathy (DR) and sight
18 threatened diabetic retinopathy (STDR), and several differences were found in
19 our study especially in blood glucose and HbA1c.
- 20 ● Owing to the multi-center design, some information was not comprehensively
21 collected, which resulted in an imperfection in risk factor analysis.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Diabetes Mellitus (DM) is a metabolic syndrome with an increasing prevalence and high rate of mortality¹. Diabetic retinopathy (DR) is a common ocular complication of DM, which is considered as a leading cause of vision loss and vision impairment in adults². With the progression of DR, quality of life of patients is getting lower and the financial burden of society is increasing, both in DR screening and therapy^{3,4}.

DR has been considered to be correlated with many other diabetes-related complications, like nephropathy, peripheral neuropathy, low bone density and cardiovascular events, which impaired the quality of life and showed a high rate of mortality⁵⁻⁸. Therefore, early diagnosis and management of DR also indicated a realistic significance.

A great deal of epidemiologic studies of DR, either cross-sectional studies⁹⁻¹⁸ or cohort studies¹⁹⁻²⁸, are conducted worldwide, exploring the risk factors that is associated with the disease and aiming at the prevention and management of disease. Older age, female, duration of diabetes, renal complications of diabetes, poor glycemic control, high lipid levels, hypertension were already reported as risk factors of DR or has an impact on DR progression⁹⁻²⁶, which was often evaluated using Treatment Diabetic Retinopathy Study (ETDRS) classification²⁷. Of these reported risk factors, duration of diabetes, hyperglycemia and hypertension were considered as most important risk factors for progression of vision loss²⁹. However, DR and risk factors of DR always gained little attention, and the compliance of eye screening is

1
2
3
4 often unsatisfied³⁰. More studies and publicity of risk factors are required.
5
6

7
8 In China, a few studies are reported and all these population-based studies are
9
10 conducted in a limited area^{21,25,28}. Therefore, a cross-sectional investigation in 6
11
12 provinces (both in Northern and Southern area) was conducted, and the prevalence of
13
14 DR and basic epidemiological characteristics has been reported in former published
15
16 article³¹. In this study, we aimed to explore the risk factors associated with DR in
17
18 mainland China.
19
20
21
22
23
24

25 **METHODS:**

26 **Research design:**

27
28
29 Lifeline Express Diabetic Retinopathy Screening Program was conducted nationwide,
30
31 which is a cross-sectional investigation in eight hospitals from 6 different provinces
32
33 (Shandong, Henan, Inner Mongolia, Jilin, Guangxi, Guangdong Provinces). Subjects
34
35 came from hospitals or local communities (1/3 from hospital patients, 1/3 from city
36
37 residents, and the other 1/3 from rural residents) between April 2014 and October
38
39 2015. The study protocol was approved by the Peking University Third Hospital Ethics
40
41 Committees and the written informed consent was provided for each subject. The
42
43 study was performed in accordance with the Declaration of Helsinki.
44
45
46
47
48
49

50
51 Subjects in hospital were diagnosed as DM by physicians and transferred to eight
52
53 screening clinics and subjects from community were recruited by advertisement. Of all
54
55 the screening clinics, 3 of which were in the south and the other 5 were in the north of
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

China. All subjects received a digital, colorful and non-stereoscopic retinal photograph, which was taken by a non-mydratic auto fundus camera. The photograph included 2 fields for each eye: one centered at the optic disc and the other centered at the macula.

DR/STDR diagnosis and grading:

DR was graded by trained and certified optometrists and ophthalmologists in Lifeline Lifeline Express Diabetic Retinopathy Central Assurance Centre. All of the graders underwent periodic tests to ensure the accuracy of grading. DR was graded by fundus photographs of two eyes into no retinopathy (R0) and diabetic retinopathy (other stages), and DR was also graded as none sight-threatening diabetic retinopathy (non-STDR), sight-threatening diabetic retinopathy (STDR) according to the UK guidelines³². Non-STDR was recognized as R0 and R1, and STDR was identified as present if any features of maculopathy (M1), pre-proliferative DR (R2) or PDR (R3) were found. If the fundus photographs were unrecognized which means missing or unable to diagnose due to variable reasons in both eyes like cataract and vitreous opacities, the patients were excluded. If photograph of one eye was unrecognized, the final diagnosis was determined by the only remained photograph. If the remained photograph was graded as R0, patients were excluded due to lack of evidence, if graded as R1, patients were diagnosed as DR and excluded for the STDR analysis, if graded as M1, R2 or R3, patients were diagnosed as DR and STDR.

Information collection:

1
2
3
4 At the time of clinical visit, the following information was recorded including gender,
5
6 age, diagnosis age, diabetes duration(calculated from age and onset age), diabetes
7
8 types (evaluated by physicians in screening clinics), body mass index (BMI,
9
10 calculated from measured height and weight), waist–hip ratio (WHR, calculated from
11
12 measured waistline and hipline), and types of medication therapy. Systolic blood
13
14 pressure(SBP), diastolic blood pressure (DBP), fasting blood-glucose (FBG),
15
16 postprandial blood glucose 2 hours after eating (PBG) and glycosylated
17
18 hemoglobin(HbA1c) was measured at the screening clinics, and fasting blood
19
20 samples were collected for cholesterol, triglyceride, high density lipoprotein(HDL), low
21
22 density lipoprotein(LDL), blood urea nitrogen(BUN), serum creatinine(SCr). Gender,
23
24 age, diagnosis age, diabetes duration, blood pressure, FBG and HbA1c was
25
26 screened for each patient, while other information was limited due to environment and
27
28 devices.
29
30
31
32
33
34
35
36
37
38

39 **Statistical analysis:**

40 Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL)
41
42 software. The independent t-test was used to compare continuous variables, and the
43
44 chi-square test was used to compare discontinuous variables among groups. Due to
45
46 limited numbers of type 1 and gestational diabetic patients, we only analyzed the data
47
48 of type 2 diabetic patients.
49
50

51
52 We firstly conducted analysis of relationship between the risk factors and DR, which
53
54 contains 3 major steps. In the first step, mean values and median values of the main
55
56 variables were calculated. In the second step, univariate analyses of the associations
57
58
59
60

1
2
3
4 between the existence of DR and other risk factors. In this step, several continuous
5
6 variables, including age, diabetes duration, blood pressure (BP), BMI, WHR were also
7
8 transferred into categorical variables, to explore detailed relationship with DR. Age
9
10 was divided into groups with 10-year interval, and diabetes duration with 5-year
11
12 interval. BP was transferred into normal BP, level 1 hypertension, level 2 hypertension,
13
14 and severe hypertension³³. BMI was divided into underweight (<18.5), normal weight
15
16 (≥ 18.5 & <24), overweight (≥ 24 & <27) and obesity (≥ 27). WHR was divided into
17
18 normal WHR (male ≤ 0.90 & female ≤ 0.85) and abdominal obesity (male 0.90 &
19
20 female ≤ 0.85), and was also divided into male and female. In the third step,
21
22 multicollinearity diagnosis was performed and a variance inflation factor (VIF) >10
23
24 was thought a high collinearity³⁴, furthermore, variables with high collinearity were
25
26 evaluated and variable which was more relevant to the research purpose was
27
28 remained determined by two researchers (YJR and LY). In the fourth step, binary
29
30 logistic regression analyses were carried out, taking the existence of DR as the
31
32 dependent variable and all risk factors, which were significantly associated with the
33
34 existence of DR in the former step or considered as an important risk factor based on
35
36 existed studies, as independent variables. Due to limitations of information collection,
37
38 we separately analyzed the eight risk factors which was completely collected in each
39
40 screening clinics (eight-factor analysis), and all risk factors (all-factor analysis),
41
42 furthermore, difference between two analyses was discussed.
43
44
45
46
47
48
49
50
51
52

53 Then, relationship between the risk factors and STDR was also conducted in previous
54
55 way. Odds ratios (ORs) and 95% confidence intervals were presented. An α level of
56
57
58
59
60

0.05 was adopted as the significance level.

At last, nomograms for DR and STDR risk factors were developed, and risk factors that showed significant difference in former binary logistic regression were treated as predictors. Interpretation of the nomogram in prediction of DR has been reported in former studies³⁵, and using each score of predictors, risk incidence of DR and STDR would be calculated.

Results:

From April 2014 to October 2015, 13473 DM patients from 6 provinces were enrolled in the study. 45.9% patients were from southern provinces (6180/13473) and 54.1% from northern provinces (7293/13473). Of all the patients, 13304 patients were type 2 diabetes, 96 were type 1 diabetes, and 73 were gestational diabetes. Patients were divided into no DR and DR, non-STDR and STDR, according to the fundus photographs grading. 571 patients were excluded from DR risk factor analysis, and 683 patients were excluded from STDR risk factor analysis due to diagnostic rules mentioned above, and finally 12733 patients were included in DR risk factor analysis and 12621 patients were included in STDR risk factor analysis (shown in Figure 1).

Firstly, analyses of DR risk factors were performed, and basic characteristics of all risk factors were shown in Table 1. The result of univariate analyses indicated that age, diagnosis age, diabetes duration, SBP, DBP, waistline, hipline, WHR, medicine (oral and insulin), FBG, PBG, HbA1c, BUN, and LDL was statistically significantly different between groups ($p < 0.05$), and no significant difference was found in gender, BMI, Cr, cholesterol, triglyceride, and HDL ($p > 0.05$).

1
2
3
4 Furthermore, categorical analyses showed that patients were getting less likely to
5
6 suffer from DR per 10 years after 60 years old, while no difference was found before
7
8 60. Incidence of DR increased significantly per 5-year diabetes duration, while it
9
10 stopped increasing after 20 years of diabetes duration. Results of blood pressure
11
12 indicated that incidence increased with the rise of level, and when it came to level 3
13
14 BP, it didn't differ from level 2. Female had a higher WHR in DR while male didn't, and
15
16 whether in a condition of abdominal obesity didn't influence the incidence of DR.
17
18

19
20 Then, multivariate analyses were performed. Multicollinearity diagnosis was
21
22 performed in both eight-factor analysis and all-factor analysis. The results excluded
23
24 diagnosis age (highly correlated to age and DR duration) in eight-factor analysis, and
25
26 excluded diagnosis age (highly correlated to age and DR duration), waistline, hipline
27
28 (both of which highly correlated to WHR) in all-factor analysis due to the high
29
30 collinearity. Multiple logistic regression analyses were carried out and the results were
31
32 shown in Table 3. Results of eight-factor analysis (with diagnosis age excluded)
33
34 showed that younger age, longer diabetes duration, higher SBP, higher FBG, and
35
36 higher HbA1c was the independent risk factor for DR ($p < 0.05$), and sex, DBP was not
37
38 significantly associated with DR ($p > 0.05$). Multiple logistic regression of all-factor
39
40 analysis (with diagnosis age, waistline, hipline excluded) was also conducted and the
41
42 result showed that younger age, longer diabetes duration, higher SBP, HbA1c, PBG,
43
44 oral medicine, insulin use, higher triglyceride, and higher LDL were the independent
45
46 risk factors for DR ($p < 0.05$), while sex, DBP, BMI, FBG, WHR, BUN, Cr, cholesterol,
47
48 and HDL were not associated with DR ($p > 0.05$).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 After DR risk factors analyses, analyses of STDR risk factors were conducted, and
5
6 characteristics of risk factors were shown in Table 2. Age, diagnosis age, diabetes
7
8 duration, SBP, DBP, HbA1c, FBG, PBG, waistline, WHR, medicine, Cr, LDL showed
9
10 statistically significant difference between groups ($p<0.05$), while gender, BMI, hipline,
11
12 BUN, cholesterol, triglyceride, HDL was not significantly different. After
13
14 multicollinearity diagnosis, diagnosis age was dropped in eight-factor analysis and
15
16 diagnosis age, waistline and hipline were dropped in all-factor analysis. Result of
17
18 multiple logistic regression was shown in Table 3. Results of eight-factor analysis (with
19
20 diagnosis age dropped) showed that younger age, longer diabetes duration, higher
21
22 SBP, DBP, FBG, and HbA1c were the independent risk factor for STDR ($p<0.05$), and
23
24 sex was not significantly associated with STDR ($p>0.05$). Results of all-factor analysis
25
26 indicated that younger age, longer diabetes duration, higher SBP, higher FBG, oral
27
28 medicine and insulin use were regarded as independent risk factors for STDR ($p<0.05$)
29
30 while other risk factors showed no significant difference ($p>0.05$).
31
32
33
34
35
36
37
38
39 Finally, we developed a nomogram to simplify the presentation and understanding of
40
41 our results (Figure 2).
42

43 **Discussion:**

44
45
46 According to the result of our study, we tried to find a reasonable explanation and an
47
48 internal relationship between DR, STDR and risk factors.
49

50
51
52 Firstly, focusing on univariate analysis, 14 out of 20 risk factors were observed
53
54 significantly different between no DR and DR, and 13 out of 20 factors between
55
56 non-STDR and STDR. Basically, all risk factors were divided into incontrollable and
57
58
59
60

1
2
3
4 controllable risk factors.

5
6 Incontrollable factors included gender, age, diagnosis age, and diabetes duration. In
7
8 both no DR/ DR and non-STDR/STDR analysis, gender showed no difference, which
9
10 was also reported in several previous studies ^{10, 12}, while results of some studies were
11
12 controversial ^{11,13}. Significantly younger age was observed in DR and STDR, and
13
14 longer duration of diabetes was also found in DR and STDR. Longer duration may
15
16 represent a longer time of retinal toxicity to retina induced by high glucose, which was
17
18 thought to be associated with both vascular and neural death in retina ³⁶. Existed
19
20 studies showed an older or extreme younger age in DR patients than no DR patients
21
22 ²⁶, while older age was thought as a protective variable for DR/STDR in our study,
23
24 especially in DM patients older than 60. We thought that the possible reason of this
25
26 phenomenon was that younger age of DM diagnosis played an important role in DR
27
28 and STDR progression, which may be explained by genetic differences ¹⁸.
29
30 Furthermore, we explored the relationship between age and HbA1c, diabetes duration,
31
32 medicine, the results indicated that with age increasing, diabetes duration increased,
33
34 while HbA1c and use of insulin decreased, which implied that although the duration of
35
36 diabetes increased, older people had a better glucose management and required
37
38 milder medicine. In this way, age was analyzed as a protective factor.

39
40 Controllable risk factors included types of variables as following: index of obesity,
41
42 blood pressure, medicine, blood glucose, renal function and blood lipid. Both DR and
43
44 STDR showed a significantly higher WHR, blood pressure, blood glucose, LDL and a
45
46 higher incidence of insulin use than no DR and non-STDR, and BUN was only
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 significantly higher in DR than no DR, while Cr was only significantly higher in STDR
4
5
6 than non-STDR. WHR was thought to be associated with DM ³⁷, and was also thought
7
8 as a risk factor for severe DR in women ³⁸, and our study showed similar results in
9
10 univariate analysis. High blood pressure indicated a significantly higher incidence of
11
12 DR and STDR, while the effect didn't increase after a certain level. Blood glucose and
13
14 LDL were significantly higher in DR and STDR group than no DR and non-STDR
15
16 group, while cholesterol level showed no significant difference, which indicated DR
17
18 and STDR group had a bad management of blood glucose and LDL. BUN and Cr
19
20 were both common variables that reflected renal function, and our study indicated that
21
22 DR and STDR showed a higher level of renal injury than no DR and non-STDR.
23
24 Application of oral medicine and insulin was also reported as risk factors in former
25
26 studies, which may be owing to the severity of disease condition ¹¹.
27
28

29
30
31
32
33 Secondly, the results of multiple logistic regression analyses showed independent risk
34
35 factors of DR and STDR were similar in eight-factor analysis (with diagnosis age
36
37 dropped) and were kind of different in all-factor analysis (with diagnosis age, waistline,
38
39 hipline dropped). In all-factor analysis, age, diabetes duration and SBP were
40
41 independent risk factors for both DR and STDR, while PBG, HbA1c, Triglyceride and
42
43 LDL were independent risk factors only for DR, and FBG only for STDR. Age,
44
45 diabetes duration and SBP has been reported as independent risk factors for DR or
46
47 DR progression ^{10,20,25}, while differences on blood glucose were hard to explain.
48
49 HbA1c has been reported to be an independent risk factor in development and
50
51 progression of DR in former studies ^{18,21}, while there existed little evidence on PBG in
52
53
54
55
56
57
58
59
60

1
2
3
4 DR progression. HbA1c was long considered to represent the management condition
5
6 of blood glucose, and bad glucose management contributed to the occurrence and
7
8 progression of DR ^{9,10,11}. PBG was reported to be abnormal in 31% DM patients
9
10 whose FBG was normal ³⁹, so it was considered an important diagnostic factor for DM.
11
12 PBG was more valuable in prediction of ischemic and hemorrhagic stroke,
13
14 cardiovascular disease mortality, while FBG was weak in prediction ^{40,41}, therefore, we
15
16 thought that PBG was a risk factor for severe complications of DM, such as DR.
17
18 Possible mechanism of PBG in progression of DR is PBG reflected capacity of insulin
19
20 secretion, the peak of which was shown to be delayed in type 2 DM ⁴², and high level
21
22 of PBG indicated that insulin secretion was relatively insufficient which may result in a
23
24 blood glucose fluctuation after food intake, and did more harm to targeted organs. Our
25
26 study firstly found that FBG was an independent risk factor for STDR, meanwhile we
27
28 also admit that OR was only 1.043 for 1 unit increase in FBG, which had limited
29
30 meaning in predicting incidence of STDR, which was also indicated in nomogram. No
31
32 existed studies showed that FBG was an independent risk factor for DR, which may
33
34 be caused by a higher predictive value of HbA1c in these studies, and possible
35
36 mechanism of FBG for STDR required further studies. LDL and triglyceride were also
37
38 independent risk factors for DR, which indicated that management of blood lipids were
39
40 very important for occurrence of DR, while it had limited meanings for STDR
41
42 compared with other risk factors.
43
44
45
46
47
48
49
50
51
52

53
54 Our study also had some limitations. Firstly, due to limitations of device and screening
55
56 environment, several variables were incomplete and if we meant to analyze all
57
58
59
60

1
2
3 variables in this study, lots of data would be abandoned, and the result of multivariate
4
5 regression may be influenced. Secondly, although we tried to balance the resources
6
7 of patients, from north and south, from urban and rural areas, patients enrolled in final
8
9 all-factor logistic regression were not fully balanced due to the exclusion of missing
10
11 data. Thirdly, patients and screening clinics were not stratified sampled, and couldn't
12
13 fully represent the patient in mainland China. Fourthly, our study design was
14
15 cross-sectional, compared to cohort studies, cross-sectional studies had weaker
16
17 strength of evidence, and the results should be carefully explained. More cohort
18
19 studies focusing on several areas of China was required.
20
21
22
23
24

25 26 **Conclusions:**

27
28 Our study demonstrated that age, diabetes duration and SBP were independent risk
29
30 factors for both DR and STDR. PBG, HbA1c, Triglyceride and LDL were independent
31
32 risk factors only for DR, and FBG only for STDR. This result was similar to existed
33
34 studies and may provide some evidence on clinical prevention of DR and STDR,
35
36 especially we firstly brought up that FBG, PBG, HbA1c were all important predictors
37
38 for occurrence or progression of DR, and this required a stricter glucose control. More
39
40 DR screening and information collection were required, which may decrease the
41
42 incidence of DR and improved clinical results.
43
44
45
46
47
48
49
50

51 **Acknowledgements:**

52 **Ownership of the program:**

53
54 Chinese Foundation for Lifeline Express and Lifeline Express Hong Kong Foundation.
55
56
57
58
59
60

Funding/Support:

This study was also supported by Beijing Municipal Science & Technology Commission. Grant Number: Z141107002514042

Conflicts of interest: No potential conflicts of interest were reported.

Author Contributions: Y.L. and J.Y designed the whole study, completed the data collection, and wrote the manuscript. J.Y and L.T performed the data analysis and L.T contributed to the writing of the manuscript on epidemic part. H.L. and X.J. contributed to the study design, and contributed to the writing of the manuscript. M.Z. assisted with the study design, data collection and contributed to the editing of the manuscript. X.L. oversaw the study, gave advise on study design, and revised the manuscript. X.L. is the guarantor of this study and had full access to all the data in this study, and X.L. also takes responsibility for the integrity of the data and the accuracy of the data analysis.

Reference:

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. *Diabetes Care*. 1998; 21: 1414-31.
2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. *Lancet Glob Health*. 2013;1(6):e339–49
3. Jones S, Edwards R T. Diabetic retinopathy screening: a systematic review of the economic evidence. *Diabet Med*. 2010, 27(3):249–256.
4. Heintz, E., Wiréhn, A.B., Peebo, B.B., et al. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. *Diabetologia*. 53(10), 2147–2154 (2010)
5. Moriya T, Tanaka S, Sone H, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. *J Diabetes Complications*. 2016 Jun 29. pii: S1056-8727(16)30224-0.
6. de Moraes G1, Layton CJ. Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy. *Clin Experiment Ophthalmol*. 2016 Jun 23.
7. Lim Y, Chun S, Lee JH, et al. Association of bone mineral density and diabetic retinopathy in diabetic subjects: the 2008-2011 Korea National Health and Nutrition Examination Survey. *Osteoporos Int*. 2016 Jul;27(7):2249-57.
8. Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study. *Ophthalmology*. 2013;120(3):574–82.

9. Knudsen L L, Lervang H H, Lundbye-Christensen S, et al. The North Jutland County Diabetic Retinopathy Study: population characteristics. *Br J Ophthalmol*. 2006, 90(11):1404-9.

10. Bertelsen G, Peto T, Lindekleiv H, et al. Tromsø eye study: prevalence and risk factors of diabetic retinopathy. *Acta Ophthalmol*, 2013, 91(8):716-21.

11. Dr. Xinzhi Zhang, Dr. Jinan B. Saaddine, Dr. Chiu-Fang Chou, et al. Prevalence of Diabetic Retinopathy in the United States, 2005–2008. *JAMA*. 2010, 304(6):649-656.

12. Piermarocchi R, Piermarocchi S, Tognetto D, et al. Prevalence of Diabetic Retinopathy and Its Risk Factors in the PAMDI Population of the Mediterranean Basin. *Eur J Ophthalmol*. 2015, 25(3).

13. George M, Harper R, Balamurugan A, et al. Diabetic retinopathy and its risk factors in a population-based study. *J Prim Care Community Health*. 2011, 2(2):122-126.

14. Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. *Ophthalmic Epidemiol*. 2010 Aug;17(4):251-65.

15. Dedov I, Maslova O, Suntsov Y, et al. Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. *Rev Diabet Stud*. 2009, 6(2):124-9.

16. Pugliese G, Solini A, Zoppini G, et al. High prevalence of advanced retinopathy in

1
2
3
4 patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events
5
6 (RIACE) Italian Multicenter Study. *Diabetes Res Clin Pract.* 2012, 98(2):329–337.
7

8
9 17. Villena J E, Yoshiyama C A, Sánchez J E, et al. Prevalence of diabetic retinopathy
10
11 in Peruvian patients with type 2 diabetes: results of a hospital-based retinal
12
13 telescreening program. *Rev Panam Salud Publica.* 2011, 30(5):408-14.
14

15
16 18. Esteves J F, Kramer C K, Azevedo M J, et al. Prevalence of diabetic retinopathy in
17
18 patients with type 1 diabetes mellitus. *Rev Assoc Med Bras.* 2009, 55(3):268-73.
19

20
21 19. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, et al. Ten-year
22
23 incidence of diabetic retinopathy and macular edema. Risk factors in a sample of
24
25 people with type 1 diabetes. *Diabetes Res Clin Pract.* 2011, 94(1):126-32.
26
27

28
29 20. Kajiwara A, Miyagawa H, Saruwatari J, et al. Gender differences in the incidence
30
31 and progression of diabetic retinopathy among Japanese patients with type 2
32
33 diabetes mellitus: A clinic-based retrospective longitudinal study. *Diabetes Res Clin*
34
35 *Pract.* 2014, 103(3):7-10.
36
37

38
39 21. Tam V H, Lam E P, Chu B C, et al. Incidence and progression of diabetic
40
41 retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. *J Diabetes*
42
43 *Complications.* 2008, 23(3):185-93.
44
45

46
47 22. Henricsson M, Nyström L, Blohmé G, et al. The incidence of retinopathy 10 years
48
49 after diagnosis in young adult people with diabetes: results from the nationwide
50
51 population-based Diabetes Incidence Study in Sweden (DISS). *Diabetes Care.* 2003,
52
53 26(2):349-354.
54
55

56
57 23. Stratton I M, Kohner E M, Aldington S J, et al. UKPDS 50: Risk factors for
58
59
60

1
2
3
4 incidence and progression, of retinopathy in Type II diabetes over 6 years from
5
6 diagnosis. *Diabetologia*. 2001, 44(2):156-63.
7

8
9 24. Salinerofort M Á, Burgoslunar C D, Arrietablanco F J, et al. Four-Year Incidence of
10
11 Diabetic Retinopathy in a Spanish Cohort: The MADIABETES Study. *PLoS One*.
12
13 2012, 8(8):377-380.
14

15
16 25. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence
17
18 of diabetic retinopathy. The Beijing Eye Study 2001/2011. *PLoS One*.
19
20 2014;9(10):e1111320.
21
22

23
24 26. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of
25
26 diabetic retinopathy during 17 years of a population-based screening program in
27
28 England. *Diabetes Care*. 2012;35(3):592-6.
29

30
31 27. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS
32
33 report number 12. Early Treatment Diabetic Retinopathy Study Research Group.
34
35 *Ophthalmology*. 1991;98(5 Suppl):823-33.
36
37

38
39 28. Yan ZP, Ma JX. Risk factors for diabetic retinopathy in northern Chinese patients
40
41 with type 2 diabetes mellitus. *Int J Ophthalmol*. 2016 Aug 18;9(8):1194-9.
42

43
44 29. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic
45
46 macular edema and related vision loss. *Eye Vis (Lond)*. 2015 Sep 30;2:17.
47
48

49
50 30. Zhou M, Astell-Burt T, Bi Y, et al. Geographical variation in diabetes prevalence
51
52 and detection in china: multilevel spatial analysis of 98,058 adults. *Diabetes Care*.
53
54 2015;38(1):72-81.
55

56
57 31. Liu Y, Song Y, Tao L, et al. Prevalence of diabetic retinopathy among 13473
58
59
60

1
2
3
4 patients with diabetes mellitus in China: a cross sectional epidemiological survey in
5
6 six provinces. *BMJ Open* 2017;7:e013199. doi:10.1136/bmjopen-2016-013199

7
8
9 32. Harding S, Greenwood R, Aldington S, et al. Grading and disease management in
10
11 national screening for diabetic retinopathy in England and Wales. *Diabet Med*.
12
13 2003;20(12):965-971.

14
15
16 33. BCGuidelines.ca: Hypertension – Diagnosis and Management (2015). Available
17
18 at: www.bcguidelines.ca

19
20
21 34. Mansfield ER, Helms BP. Detecting multicollinearity. *Am Stat*. 1982;36(3):158–60.

22
23
24 35. Semeraro F, Parrinello G, Cancarini A, Pasquini L, Zarra E, Cimino A, Cancarini G,
25
26 Valentini U, Costagliola C. Predicting the risk of diabetic retinopathy in type 2 diabetic
27
28 patients. *J Diabetes Complications*. 2011 Sep-Oct;25(5):292-7.

29
30
31 36. Nakamura M, Barber AJ, Antonetti DA, LaNoue KF, Robinson KA, et al. Excessive
32
33 hexosamines block the neuroprotective effect of insulin and induce apoptosis in
34
35 retinal neurons. *J Biol Chem*. 2011;276: 43748–43755

36
37
38 37. Fauziana R, Jeyagurunathan A, Abdin E. Body mass index, waist-hip ratio and
39
40 risk of chronic medical condition in the elderly population: results from the Well-being
41
42 of the Singapore Elderly (WiSE) Study. *BMC Geriatr*. 2016 Jun 18;16(1):125.

43
44
45 38. Man RE1, Sabanayagam C2, Chiang PP. Differential Association of Generalized
46
47 and Abdominal Obesity With Diabetic Retinopathy in Asian Patients With Type 2
48
49 Diabetes. *JAMA Ophthalmol*. 2016 Mar 1;134(3):251-7.

50
51
52 39. Eriksson J, Jousilahti P, Lindström J, et al. Is fasting glucose sufficient to define
53
54 diabetes? Epidemiological data from 20 European studies. *Diabetologia*, 1999;

1
2
3
4 Jun;42(6):647-54.
5

6 40. Hyvärinen M, Tuomilehto J, Mähönen M. Hyperglycemia and incidence of
7
8 ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose
9
10 criteria. *Stroke*. 2009 May;40(5):1633-7.
11

12
13 41. Ning F1, Tuomilehto J, Pyörälä K. Cardiovascular disease mortality in Europeans
14
15 in relation to fasting and 2-h plasma glucose levels within a normoglycemic range.
16
17 *Diabetes Care*. 2010 Oct;33(10):2211-6.
18
19

20
21 42. Guillausseau PJ, Meas T, Virally M. Abnormalities in insulin secretion in type 2
22
23 diabetes mellitus. *Diabetes Metab*. 2008 Feb;34 Suppl 2:S43-8.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figures.

Figure 1 Flow diagram of the data processing.






Figure 2 Nomograms for DR (A) and STDR (B) risk factors. Risk factors were chosen based on results of logistic regression analysis. Each risk factor of the patient was assessed on basis of the nomogram and got a point. Aggregated points of each point corresponded to a particular occurrence probability of DR or STDR.

A



B



Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1—Univariate analysis of DR risk factors. (N=12733)

Variable	n	No DR (n=8772)	n	DR (n=3961)	P	OR	95%CI
Male gender, n(%)	8772	3985 (45.4%)	3961	1851 (46.7%)	0.172		
Age, years (SD)	8770	63.0(10.3)	3959	61.0 (9.8)	<0.001		
<30, %	11	30.6%	25	69.4%			
30-40, % (vs.<30)	143	66.8%	71	33.2%	0.757	1.128	0.526-2.423
40-50, % (vs.30-40)	733	64.2%	408	35.8%	0.469	1.121	0.823-1.527
50-60, % (vs.40-50)	2138	63.2%	1243	36.8%	0.542	1.004	0.908-1.201
60-70, % (vs.50-60)	3443	69.7%	1494	30.3%	<0.001	0.746	0.680-0.819
>70, % (vs.60-70)	2217	76.0%	700	24.0%	<0.001	0.728	0.655-0.808
Diagnosis age, years (SD)	8770	56.3 (10.2)	3959	50.8 (10.3)	<0.001		
Diabetes duration, years (SD)	8772	6.7 (5.9)	3961	10.2 (6.8)	<0.001		
<5, %	4692	80.0%	1174	20.0%			
5-10, % (vs. <5)	2314	65.7%	1208	34.3%	<0.001	2.086	1.898-2.293
10-15, % (vs. 5-10)	1032	57.6%	761	42.4%	<0.001	1.413	1.257-1.587
15-20, % (vs. 10-15)	521	48.2%	560	51.8%	<0.001	1.458	1.252-1.696
>20, % (vs. 15-20)	213	45.2%	258	54.8%	0.281	1.127	0.907-1.400
BMI (SD)	6000	24.7 (3.5)	2854	24.9 (3.9)	0.116		
Underweight, %	97		53				
Normal weight, % (vs. underweight)	3348		1543		0.326	0.843	0.600-1.185
Overweight, % (vs. normal weight)	2175		1043		0.414	1.041	0.946-1.145
Obese, % (vs. overweight)	380		215		0.076	1.180	0.983-1.417
SBP, mmHg (SD)	8762	133.3 (16.5)	3952	137.0(17.9)	<0.001		
DBP, mmHg (SD)	8762	79.6 (9.9)	3952	80.8 (10.8)	<0.001		
Normal BP, %	5084	72.3%	1950	27.7%			
BP level 1, % (vs. normal)	2840	66.7%	1420	33.3%	<0.001	1.303	1.200-1.414
BP level 2, % (vs. level 1)	665	59.3%	456	40.7%	<0.001	1.371	1.198-1.569
BP level 3, % (vs. level 2)	173	57.9%	126	42.1%	0.648	1.062	0.820-1.376
Waistline, cm (SD)	5719	89.3 (10.1)	2735	90.3 (10.6)	<0.001		
Hipline, cm (SD)	5719	96.6 (9.7)	2735	97.1 (9.5)	0.028		
WHR (SD)	5719	0.926 (0.074)	2735	0.930 (0.069)	0.007		
Abdominal obesity, n(%)		4677 (81.8%)		2267 (82.9%)	0.213	1.079	0.957-1.217
Female (SD)	3152	0.915 (0.076)	1501	0.923 (0.072)	0.002		
Male (SD)	2567	0.94 (0.070)	1234	0.94 (0.064)	0.674		

Medicine	5793		2797		<0.001		
No medicine, %	660	87.0%	99	13.0%			
Oral medicine, %	3296	73.2%	1208	26.8%	<0.001	5.407	4.331-6.752
(vs. no medicine)							
Insulin, %	1837	55.2%	1490	44.8%	<0.001	2.213	2.013-2.434
(vs. oral medicine)							
FBG, mmol/L (SD)	7547	7.8 (2.4)	3517	8.7 (3.0)	<0.001		
PBG, mmol/L (SD)	4780	10.7 (3.3)	2095	11.8 (3.5)	<0.001		
HbA1c, % (SD)	7762	7.16 (1.65)	3146	7.82 (1.90)	<0.001		
BUN, mmol/L (SD)	6357	5.79 (8.19)	2633	6.33 (10.51)	0.01		
Cr, μ mol/L (SD)	6320	76.5 (112.7)	2615	78.8 (39.2)	0.328		
Cholesterol, mmol/L (SD)	6418	5.04 (2.69)	2651	5.06 (1.31)	0.752		
Triglyceride, mmol/L (SD)	6382	1.87 (1.22)	2635	1.89 (1.26)	0.456		
HDL, mmol/L (SD)	6392	1.37 (0.56)	2642	1.38 (0.57)	0.481		
LDL, mmol/L (SD)	6399	2.72 (1.00)	2643	2.83 (1.00)	<0.001		

Continuous variables were reported as mean value and standard deviation, and categorical variables were reported as percentage, OR and 95% CI. P<0.05 was considered statistically significant and marked in bold. n, number; OR, odd ratio; 95%CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist hip ratio; FBG, fasting blood glucose; PBG, postprandial blood glucose; HbA1c, glycosylated hemoglobin; BUN, blood urea nitrogen; Cr, creatinine; HDL, high density lipoprotein; LDL, low density lipoprotein.

Table 2—Univariate analysis of STDR risk factors. (N=12621)

Variable	n	None-STDR (n=10875)	n	STDR (n=1746)	P	OR	95%CI
Male gender, n(%)	10875	4985 (45.8%)	1746	799 (45.8%)	0.952		
Age, years (SD)	10873	62.7 (10.2)	1745	60.4 (9.7)	<0.001		
<30, %	32		4				
30-40, % (vs.<30)	181		32		0.757	1.128	0.526-2.423
40-50, % (vs.30-40)	927		205		0.469	1.121	0.823-1.527
50-60, % (vs.40-50)	2785		576		0.542	1.004	0.908-1.201
60-70, % (vs.50-60)	4253		643		<0.001	0.746	0.680-0.819
>70, % (vs.60-70)	2160		270		<0.001	0.728	0.655-0.808
Diagnosis age, years (SD)	10873	55.4 (10.4)	1745	49.4 (10.4)	<0.001		
Diabetes duration, years (SD)	10875	7.2 (6.2)	1746	11.0 (6.8)	<0.001		
<5, %	4692		1174				
5-10, % (vs. <5)	2314		1208		<0.001	2.086	1.898-2.293
10-15, % (vs. 5-10)	1032		761		<0.001	1.413	1.257-1.587
15-20, % (vs. 10-15)	521		560		<0.001	1.458	1.252-1.696
>20, % (vs. 15-20)	213		258		0.281	1.127	0.907-1.400
BMI (SD)	7518	24.8 (3.6)	1256	24.8 (3.9)	0.738		
Underweight	120		28				
Normal weight, % (vs. underweight)	4145		703		0.134	0.727	0.478-1.105
Overweight, % (vs. normal weight)	2759		428		0.177	0.915	0.804-1.041
Obese, % (vs. overweight)	494		97		0.054	1.266	0.995-1.610
SBP, mmHg (SD)	10863	133.8 (16.7)	1741	138.1 (18.7)	<0.001		
DBP, mmHg (SD)	10863	79.8 (10.0)	1741	81.0 (11.4)	<0.001		
Normal BP, %	6164	88.2%	826	11.8%			
BP level 1, % (vs. normal BP)	3584	85.0%	630	15.0%	<0.001	1.312	1.173-1.467
BP level 2, % (vs. BP level 1)	892	80.5%	216	19.5%	<0.001	1.378	1.161-1.635
BP level 3, % (vs. BP level 2)	223	76.4%	69	23.6%	0.118	1.278	0.939-1.739
Waistline, cm(SD)	7176	89.4 (10.1)	1200	90.7 (10.8)	<0.001		
Hipline, cm(SD)	7176	96.7 (9.6)	1200	97.2 (10.1)	0.120		
WHR (SD)	7176	0.926 (0.073)	1200	0.934(0.071)	0.001		
Abdominal obesity,n(%)		5872(81.8%)		1004(83.7%)	0.124	1.113	0.970-1.276
Female (SD)	3947	0.92 (0.075)	666	0.93 (0.074)	<0.001		

1								
2								
3	Male (SD)	3229	0.94 (0.069)	534	0.94 (0.065)	0.634		
4	Medicine	7304		1218		<0.001		
5	No medicine, %	727	93.7%	49	6.3%			
6	Oral medicine, %	4008	89.6%	465	10.4%	<0.001	2.908	1.982-4.267
7	(vs. no medicine)							
8	Insulin, %	2569	78.0%	724	22.0%	<0.001	2.429	2.140-2.757
9	(vs. oral medicine)							
10	FBG, mmol/L (SD)	9451	8.0 (2.5)	1521	8.9 (3.1)	<0.001		
11	PBG, mmol/L (SD)	5964	10.9 (3.3)	886	11.9 (3.6)	<0.001		
12	HbA1c, % (SD)	9548	7.25 (1.70)	1280	8.05 (1.97)	<0.001		
13	BUN, mmol/L (SD)	7855	5.89 (9.38)	1072	6.38 (4.99)	0.092		
14	Cr, µmol/L (SD)	7812	76.2 (102.1)	1060	84.2 (52.3)	0.012		
15	Cholesterol, mmol/L (SD)	7927	5.05 (2.48)	1079	5.06 (1.29)	0.904		
16	Triglyceride, mmol/L (SD)	7884	1.87 (1.22)	1072	1.94 (1.29)	0.072		
17	HDL, mmol/L (SD)	7897	1.37 (0.56)	1074	1.38 (0.54)	0.755		
18	LDL, mmol/L (SD)	7907	2.74 (0.99)	1072	2.82 (1.06)	0.015		
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								
31								
32								
33								
34								
35								
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								
47								
48								
49								
50								
51								
52								
53								
54								
55								
56								
57								
58								
59								
60								

Table 3 —Logistic regression of DR and STDR risk factors. (Both in eight-factor analysis and all-factor analysis.)

Variable	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
	DR risk factors analysis						DR risk factors analysis					
	eight-factor analysis (N=9367)			all-factor analysis (N=4623)			eight-factor analysis (N=9303)			all-factor analysis (N=4597)		
Sex (women vs men)	1.026	0.932-1.130	0.169	1.052	0.913-1.213	0.489	0.979	0.855-1.120	0.753	1.176	0.960-1.442	0.118
Age	0.966	0.961-0.971	<0.001	0.968	0.961-0.976	<0.001	0.961	0.954-0.968	<0.001	0.961	0.950-0.972	<0.001
Diabetes duration	1.102	1.093-1.111	<0.001	1.071	1.059-1.084	<0.001	1.102	1.091-1.113	<0.001	1.077	1.061-1.094	<0.001
SBP	1.015	1.011-1.018	<0.001	1.016	1.010-1.021	<0.001	1.017	1.011-1.021	<0.001	1.017	1.010-1.024	<0.001
DBP	0.995	0.989-1.001	0.083	0.994	0.986-1.002	0.152	0.987	0.980-0.995	0.002	0.990	0.979-1.002	0.095
FBG	1.040	1.019-1.062	<0.001	1.008	0.972-1.046	0.666	1.043	1.016-1.071	0.002	1.076	1.028-1.127	0.002
HbA1c	1.164	1.128-1.201	<0.001	1.102	1.051-1.156	<0.001	1.168	1.172-1.250	<0.001	1.060	0.994-1.130	0.077
PBG				1.039	1.014-1.065	0.003				1.013	0.979-1.048	0.473
BMI				0.991	0.972-1.012	0.406				0.976	0.948-1.005	0.109
WHR				1.527	0.591-3.947	0.382				3.314	0.927-11.842	0.065
Medicine												
Oral vs. no medicine				2.158	1.517-3.069	<0.001				3.737	1.721-8.113	0.001
Insulin vs. no medicine				3.535	2.455-5.089	<0.001				6.856	3.141-14.966	<0.001
BUN				1.004	0.997-1.011	0.238				1.002	0.994-1.010	0.598
Cr				1.000	1.000-1.001	0.745				1.000	1.000-1.001	0.121
Cholesterol				0.999	0.955-1.044	0.948				0.995	0.924-1.071	0.890
Triglyceride				0.924	0.873-0.979	0.007				0.950	0.878-1.028	0.200

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

HDL	1.030	0.901-1.176	0.668	0.970	0.789-1.193	0.776
LDL	1.099	1.017-1.187	0.017	1.093	0.978-1.221	0.118

P<0.05 was considered statistically significant and marked in bold.

For peer review only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4, 5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	23
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	25-26
		(b) Indicate number of participants with missing data for each variable of interest	25-26
Outcome data	15*	Report numbers of outcome events or summary measures	25-26
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	25-26
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risk Factors of Diabetic Retinopathy and Sight Threatened Diabetic Retinopathy: A Cross-sectional Study in 13473 Patients with Type 2 Diabetes Mellitus in Mainland China.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016280.R1
Article Type:	Research
Date Submitted by the Author:	07-May-2017
Complete List of Authors:	Liu, Yan; Peking University Third Hospital, Department of Ophthalmology Yang, Jiarui; Peking University Third Hospital, Department of Ophthalmology Tao, Liyuan; Peking University Third Hospital, Research Center of Clinical Epidemiology Lv, Hui bin; Peking University Third Hospital, Department of Ophthalmology Jiang, Xiaodan; Peking University Third Hospital, Department of Ophthalmology Zhang, Mingzhou; Peking University Third Hospital, Department of Ophthalmology Li, Xuemin; Peking University Third Hospital, Department of Ophthalmology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology, Medical management
Keywords:	Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, risk factor, blood glucose, WHR, BMI

SCHOLARONE™
Manuscripts

1
2
3
4 Title: Risk Factors of Diabetic Retinopathy and Sight Threatened Diabetic Retinopathy:
5
6 A Cross-sectional Study in 13473 Patients with Type 2 Diabetes Mellitus in Mainland
7
8 China.
9

10
11 Running title: Risk factors of DR and STDR in China
12

13
14 Authors: Yan Liu MD^{1*}, Jiarui Yang MD^{1*}, Liyuan Tao PhD², Huibin Lv MD¹, Xiaodan
15
16 Jiang MD¹, Mingzhou Zhang MD¹, Xuemin Li MD¹
17

18
19 * These authors contributed equally to this work.
20

21
22 1 Department of Ophthalmology, Peking University Third Hospital
23

24
25 2 Research Center of Clinical Epidemiology, Peking University Third Hospital
26

27
28 Corresponding author: Xuemin Li MD
29

30
31 Address: Department of Ophthalmology, Peking University Third Hospital,
32

33
34 No.49Huayuan North Street, Haidian District, Beijing, China
35

36
37 Email: 13911254862@163.com; lxm1xm66@sina.com.cn
38

39
40 Word count: 3776 words
41

42
43 Number of figures: 2.
44

45
46 Number of tables: 3.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Risk Factors of Diabetic Retinopathy and Sight Threatened Diabetic**
5
6 **Retinopathy:A Cross-sectional Studyin 13473 Patients with Type 2 Diabetes**
7
8 **Mellitus in Mainland China**
9

10
11 **Abstract:**
12

13
14 **Objective:** To explore the risk factors of diabetic retinopathy (DR) and sight
15 threatened diabetic retinopathy (STDR) among Chinese patients with diabetes.
16
17

18
19 **Design, setting and participants:** A cross-sectional investigation was performed in
20 eight screening clinics in six provinces across mainland China. Information of risk
21 factors was recorded in screening clinics, and in these risk factors, sex, age,
22 diagnosis age, diabetes duration, SBP, DBP, FBG, HbA1c were recorded in each
23 clinic while others were partially collected. Relationship between risk factors and DR,
24 risk factors and STDR were explored in both eight factors mentioned above and all
25 factors.
26
27
28
29
30
31
32
33
34
35

36 **Main outcomes and measures:** Risk factors of DR and STDR, and a nomogram of
37 the results.
38
39

40
41 **Results:** Younger age, longer diabetes duration, higher SBP, higher FBG, and higher
42 HbA1c were independent risk factors for both DR and STDR in eight-factor analyses.
43
44 In all-factor analysis, younger age, longer diabetes duration, higher SBP, oral
45 medicine, and insulin use were independent risk factors for both DR and STDR, while
46 higher PBG, HbA1c, triglyceride and LDL were independent risk factors only for DR,
47 and higher FBG only for STDR.
48
49
50
51
52
53
54

55
56 **Conclusions:** In this cross-sectional investigation, several risk factors were found for
57
58
59
60

1
2
3
4 DR and STDR. What's worth to mention is that FBG, PBG and HbA1c were all risk
5
6 factors for DR or STDR, which implied that a stricter blood glucose control for clinical
7
8 practice was required.
9

10
11 **Key words:** diabetic retinopathy, risk factor, glucose, WHR, BMI
12

13 14 15 **Strength and limitations of this study** 16

- 17 ● This is a cross-sectional population-based (13473 subjects) investigation of the
18 risk factors of diabetic retinopathy
19
- 20 ● The study was performed in eight hospitals from 6 different provinces in mainland
21 China, and participants were from hospitals and communities which included
22 rural and urban regions.
23
- 24 ● We separately analyzed the risk factors for diabetic retinopathy (DR) and sight
25 threatened diabetic retinopathy (STDR), which will give more implications for
26 clinical practice.
27
- 28 ● Owing to the multi-center design, some information was not comprehensively
29 collected, which resulted in an imperfection in risk factor analysis.
30
- 31 ● The sampling method of this study was not stratified, which might result in a lack
32 of representativeness.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Diabetes Mellitus (DM) is a metabolic syndrome with an increasing prevalence and high rate of mortality ¹. Diabetic retinopathy (DR) is a common ocular complication of DM, which is considered as one of the leading causes of vision loss and vision impairment in adults ². With the progression of DR, quality of life of patients is getting lower and the financial burden of society is increasing, both in DR screening and treatment ^{3,4}.

DR has been considered to be correlated with many other diabetes-related complications, like nephropathy, peripheral neuropathy, low bone density and cardiovascular events, which impaired the quality of life and showed a high rate of mortality ⁵⁻⁸. Therefore, early diagnosis and proper management of DR would be of great realistic significance.

A great deal of epidemiologic studies of DR, either cross-sectional studies ⁹⁻¹⁸ or cohort studies ¹⁹⁻²⁸, were conducted worldwide, exploring the risk factors that were associated with the disease and aiming at the prevention and management of this disease. Older age, female, duration of diabetes, renal complications of diabetes, poor glycemic control, high lipid levels, hypertension were already reported as risk factors of DR or has an impact on DR progression ⁹⁻²⁶, which was often evaluated using Treatment Diabetic Retinopathy Study (ETDRS) classification ²⁷. Of these reported risk factors, duration of diabetes, hyperglycemia and hypertension were considered as most important risk factors for progression of vision loss ²⁹. However,

1
2
3 DR and risk factors of DR always gained little attention, and the compliance of eye
4
5 screening is often unsatisfied ³⁰. More studies and publicity of risk factors are
6
7 required.
8
9

10
11 In China, a few DR screening studies were conducted, while most of them were only
12
13 conducted in a limited area ^{21,25,28}. Therefore, a cross-sectional investigation in 6
14
15 provinces (including Northern and Southern part of China) was conducted, and the
16
17 prevalence of DR and basic epidemiological characteristics has been reported in
18
19 former published article ³¹. In this study, we aimed to explore the risk factors
20
21 associated with DR and STDR in mainland China.
22
23
24

25 26 **METHODS**

27 28 29 **Research design**

30
31 Lifeline Express Diabetic Retinopathy Screening Program was conducted nationwide,
32
33 which was a cross-sectional investigation in eight hospitals from 6 different provinces
34
35 (Shandong, Henan, Inner Mongolia, Jilin, Guangxi, Guangdong Provinces). Subjects
36
37 were recruited from hospitals and local communities (1/3 from hospital patients, 1/3
38
39 from city residents, and the other 1/3 from rural residents) between April 2014 and
40
41 October 2015. The study protocol was approved by Peking University Third Hospital
42
43 Ethics Committees and the written informed consent was obtained for each subject.
44
45
46
47
48 The study was performed in accordance with the Declaration of Helsinki.
49
50

51
52 Subjects in hospital were diagnosed as DM by qualified physicians and transferred to
53
54 eight screening clinics and subjects from community were recruited by advertisement,
55
56 and medical records of DM diagnosis were required when they visited the screening
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

clinics. Of all the screening clinics, 3 of which were in the south and the other 5 were in the north of China. All subjects received a digital, colorful and non-stereoscopic retinography, which was taken by a non-mydratic auto fundus camera. The photograph included 2 fields for each eye: one centered at the optic disc and the other centered at the macula.

DR/STDR diagnosis and grading:

DR was graded by trained and certified optometrists and ophthalmologists in Lifeline Express Diabetic Retinopathy Central Assurance Centre. All of the graders underwent periodic tests to ensure the accuracy of grading. Retinopathy was graded according to fundus photographs of two eyes into no DR(R0) and DR(other stages), and DR was also graded as none sight-threatening diabetic retinopathy (non-STDR), sight-threatening diabetic retinopathy (STDR) according to the UK guidelines³². Non-STDR was recognized as R0 and R1, and STDR was identified as present if any features of maculopathy (M1), pre-proliferative DR (R2) or PDR (R3) were found. If the fundus photographs were ungradable which means missing or unable to diagnose due to variable reasons in both eyes like cataract and vitreous opacities, the patients were excluded in the risk factor analysis. If photograph of one eye was unrecognized, the final diagnosis was determined by the only remained photograph. In this condition, if the remained photograph was graded as R0, patients were excluded due to lack of evidence, if graded as R1, patients were diagnosed as DR and excluded for the STDR analysis, if graded as M1, R2 or R3, patients were diagnosed as DR and STDR.

Information collection

At the time of clinical visit, the following information was recorded including gender, age, diagnosis age, diabetes duration (calculated from age and onset age), diabetes types (evaluated by physicians in screening clinics), body mass index (BMI, calculated from measured height and weight), waist-hip ratio (WHR, calculated from measured waistline and hipline), and types of treatment. Systolic blood pressure(SBP), diastolic blood pressure (DBP), fasting blood-glucose (FBG), postprandial blood glucose 2 hours after eating 75 mg glucose (PBG) and glycosylated hemoglobin (HbA1c) was measured at the screening clinics, and blood samples after fasting for 8 hours were collected for cholesterol, triglyceride, high density lipoprotein(HDL), low density lipoprotein(LDL), blood urea nitrogen(BUN), serum creatinine(Cr) measurement. Gender, age, diagnosis age, diabetes duration, blood pressure, FBG and HbA1c were collected for each patient, while other information was limited to only part of subjects due to environment and devices.

Statistical analysis

Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL) software. The independent t-test was used to compare continuous variables, and the chi-square test was used to compare discontinuous variables among groups. Due to limited numbers of type 1 and gestational diabetic patients, we only analyzed the data of type 2 diabetic patients.

We firstly conducted analysis of relationship between the risk factors and DR, which contains four major steps. In the first step, mean values and median values of the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

main variables were calculated. In the second step, univariate analyses of the associations between the existence of DR and risk factors. In this step, several continuous variables, including age, diabetes duration, blood pressure (BP), BMI, WHR were also transferred into categorical variables, to explore detailed relationship with DR. Age was divided into groups with 10-year interval, and diabetes duration with 5-year interval. BP was transferred into normal BP, level 1 hypertension, level 2 hypertension, and severe hypertension³³. BMI was divided into underweight (<18.5), normal weight (≥ 18.5 & <24), overweight (≥ 24 & <28) and obesity (≥ 28). WHR was divided into normal WHR (male ≤ 0.90 & female ≤ 0.85) and abdominal obesity (male 0.90 & female ≤ 0.85), and was also divided into male and female. In the third step, multicollinearity diagnosis was performed and a variance inflation factor (VIF) >10 was thought a high collinearity³⁴, furthermore, variables with high collinearity were evaluated and variable which was more relevant to the research purpose was remained determined by two researchers (YJR and LY). In the fourth step, binary logistic regression analyses were carried out, taking the existence of DR as the dependent variable and all risk factors, which were significantly associated with the existence of DR in the former step or considered as an important risk factor based on existed studies, as independent variables. Due to limitations of information collection, we separately analyzed the eight risk factors which was completely collected in each screening clinics (eight-factor analysis), and all risk factors (all-factor analysis), furthermore, difference between two analyses was discussed.

Then, relationship between the risk factors and STDR was also conducted in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

aforementioned way. Odds ratios (ORs) and 95% confidence intervals were calculated. An α level of 0.05 was adopted as the significance level.

At last, nomograms for DR and STDR risk factors were developed, and significant risk factors in former binary logistic regression were regarded as predictors. Interpretation of the nomogram in prediction of DR has been reported in former studies³⁵, which including two major parts. In the first part, exact values of each predictor was vertically corresponded to a certain point (the first row of the nomogram), and the total points of each predictor are calculated. In the second part, total points will corresponded to a specific risk incidence of DR and STDR (the last row of the nomogram), which will provide some implications for clinical practice.

Results

From April 2014 to October 2015, 13473 DM patients from 6 provinces were enrolled in the study. 45.9% patients were from southern provinces (6180/13473) and 54.1% from northern provinces (7293/13473). Of all the patients, 13304 patients were type 2 diabetes, 96 were type 1 diabetes, and 73 were gestational diabetes. Patients were divided into no DR and DR, non-STDR and STDR, according to the fundus photographs grading. 571 patients were excluded from DR risk factor analysis, and 683 patients were excluded from STDR risk factor analysis due to diagnostic rules mentioned above, and finally 12733 patients were included in DR risk factor analysis and 12621 patients were included in STDR risk factor analysis (shown in Figure 1).

Firstly, analyses of DR risk factors were performed, and basic characteristics of all risk factors were shown in Table 1. The result of univariate analyses indicated that age,

1
2
3
4 diagnosis age, diabetes duration, SBP, DBP, waistline, hipline, WHR, medicine (oral
5
6 medication or insulin injection), FBG, PBG, HbA1c, BUN, and LDL was statistically
7
8 significantly different between groups ($p<0.05$), and no significant difference was
9
10 found in gender, BMI, Cr, cholesterol, triglyceride, and HDL ($p>0.05$).

11
12
13
14 Furthermore, categorical analyses showed that patients were getting less likely to
15
16 suffer from DR per 10 years after 60 years old, while no difference was found before
17
18 60. Incidence of DR increased significantly per 5-year diabetes duration, while it
19
20 stopped increasing after 20 years of diabetes duration. Results of blood pressure
21
22 indicated that incidence increased with the rise of level, and when it came to level 3
23
24 BP, it didn't differ from level 2. Female had a higher WHR in DR while male did not,
25
26 and whether in a condition of abdominal obesity did not influence the incidence of DR.
27
28
29 Then, multivariate analyses were performed. Multicollinearity diagnosis was
30
31 performed in both eight-factor analysis and all-factor analysis. The results excluded
32
33 diagnosis age (highly correlated to age and DR duration) in eight-factor analysis, and
34
35 excluded diagnosis age (highly correlated to age and DR duration), waistline, hipline
36
37 (both of which highly correlated to WHR) in all-factor analysis due to the high
38
39 collinearity. Multiple logistic regression analyses were carried out and the results were
40
41 shown together with STDR analysis. Results of eight-factor analysis (with diagnosis
42
43 age excluded) showed that younger age, longer diabetes duration, higher SBP, higher
44
45 FBG, and higher HbA1c were the independent risk factor for DR ($p<0.05$), and sex,
46
47 DBP were not significantly associated with DR ($p>0.05$). Multiple logistic regression of
48
49 all-factor analysis (with diagnosis age, waistline, hipline excluded) was also
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 conducted and the result showed that younger age, longer diabetes duration, higher
5
6 SBP, HbA1c, PBG, oral medicine, insulin use, higher triglyceride, and higher LDL
7
8 were the independent risk factors for DR ($p<0.05$), while sex, DBP, BMI, FBG, WHR,
9
10 BUN, Cr, cholesterol, and HDL were not associated with DR ($p>0.05$).

11
12
13
14 After DR risk factors analyses, analyses of STDR risk factors were conducted, and
15
16 characteristics of risk factors were shown in Table 2. Age, diagnosis age, diabetes
17
18 duration, SBP, DBP, HbA1c, FBG, PBG, waistline, WHR, medicine, Cr, LDL showed
19
20 statistically significant difference between groups ($p<0.05$), while gender, BMI, hipline,
21
22 BUN, cholesterol, triglyceride, HDL were not significantly different. After
23
24 multicollinearity diagnosis, diagnosis age was excluded in eight-factor analysis and
25
26 diagnosis age, waistline and hipline were excluded in all-factor analysis. Results of
27
28 multiple logistic regression of STDR analyses (together with DR analyses) were
29
30 shown in Table 3. Results of eight-factor analysis (with diagnosis age dropped)
31
32 showed that younger age, longer diabetes duration, higher SBP, DBP, FBG, and
33
34 HbA1c were the independent risk factor for STDR ($p<0.05$), and sex was not
35
36 significantly associated with STDR ($p>0.05$). Results of all-factor analysis indicated
37
38 that younger age, longer diabetes duration, higher SBP, higher FBG, oral medicine
39
40 and insulin use were regarded as independent risk factors for STDR ($p<0.05$) while
41
42 other risk factors showed no significant difference ($p>0.05$).

43
44
45
46 Furthermore, we subcategorized non-STDR into no DR and DR but not STDR, and risk
47
48 factors between DR but not STDR and no DR, STDR and DR but not STDR were
49
50 explored. The results showed that independent risk factors for DR but not STDR
51
52
53
54
55
56
57
58
59
60

1
2
3
4 compared with no DR were exactly the same as DR/no DR. However, risk factors of
5
6 STDR compared to DR but not STDR analysis showed two new independent risk
7
8 factors, besides those for STDR/non-STDR, which were male sex and Cr.
9

10
11 Finally, we developed a nomogram to simplify the presentation and understanding of
12
13 our results (Figure 2).
14

15 16 **Discussion**

17
18 According to the result of our study, we tried to find a reasonable explanation and an
19
20 internal relationship between DR, STDR and risk factors.
21
22

23
24 Firstly, focusing on univariate analysis, 14 out of 20 risk factors were significantly
25
26 different between no DR and DR, and 13 out of 20 factors between non-STDR and
27
28 STDR. Basically, all risk factors were divided into non-modifiable and modifiable risk
29
30 factors. Non-modifiable factors included gender, age, diagnosis age, and diabetes
31
32 duration. In both no DR/ DR and non-STDR/STDR analysis, gender showed no
33
34 significant difference, which was also reported in several previous studies ^{10, 12}, while
35
36 results of some studies were controversial ^{11,13}. Significantly younger age was
37
38 observed in DR and STDR, and longer duration of diabetes was also found in DR and
39
40 STDR. Longer duration may represent a longer time of retinal toxicity induced by high
41
42 glucose, which was thought to be associated with both vascular and neural death in
43
44 retina ³⁶. Existed studies showed an older or extreme younger age in DR patients than
45
46 no DR patients ²⁶. In our study, older age was thought as a protective variable for DR,
47
48 while it's a risk variable for STDR, especially in DM patients older than 60, which
49
50 means even though older age was associated with lower incidence of DR, it's more
51
52
53
54
55
56
57
58
59
60

1
2
3
4 vision threatened. We thought that this phenomenon might be explained by the higher
5
6 mortality risk in older DR populations as DR was correlated with severe general
7
8 diseases³⁷, so this result might be related to survival bias. However, older age also
9
10 implied a longer suffering of hyperglycemia, which might be more vision threatened.
11
12 Furthermore, we explored the relationship between age and HbA1c, diabetes duration,
13
14 therapeutic regimen, the results indicated that with age increasing, diabetes duration
15
16 increased, while HbA1c and use of insulin decreased, which implied that although the
17
18 duration of diabetes increased, older people had a better glucose management and
19
20 required milder medicine. In this way, age was determined as a protective factor.
21
22 Modifiable risk factors included types of variables as following: index of obesity, blood
23
24 pressure, medicine, blood glucose, renal function and blood lipid. Both DR and STDR
25
26 showed a significantly higher WHR, blood pressure, blood glucose level, LDL and a
27
28 higher incidence of insulin use than no DR and non-STDR, and BUN was only
29
30 significantly higher in DR than no DR, while Cr was only significantly higher in STDR
31
32 than non-STDR. WHR was thought to be associated with DM³⁸, and was also thought
33
34 as a risk factor for severe DR in women³⁹. Our study showed similar results in
35
36 univariate analysis. High blood pressure indicated a significantly higher incidence of
37
38 DR and STDR, while the effect did not increase after a certain level. Blood glucose
39
40 and LDL were significantly higher in DR and STDR group than no DR and non-STDR
41
42 group, while cholesterol level showed no significant difference, which indicated DR
43
44 and STDR group had a bad management of blood glucose and LDL. BUN and Cr
45
46 were both common variables that reflected renal function, and our study indicated that
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 DR and STDR showed a higher level of renal injury than no DR and non-STDR.

5
6 Application of oral medicine or insulin was also reported as risk factors in former
7
8 studies, which may be owing to the severity of disease condition ¹¹.

9
10
11 Secondly, the results of multiple logistic regression analyses showed independent risk
12
13 factors of DR and STDR were similar in eight-factor analysis (with diagnosis age
14
15 dropped) and were kind of different in all-factor analysis (with diagnosis age, waistline,
16
17 hipline dropped). In all-factor analysis, younger age, diabetes duration and SBP were
18
19 independent risk factors for both DR and STDR, while PBG, HbA1c, Triglyceride and
20
21 LDL were independent risk factors only for DR, and FBG only for STDR. Age,
22
23 diabetes duration and SBP has been reported as independent risk factors for DR or
24
25 DR progression ^{10,20,25}, while differences on blood glucose were hard to explain.
26
27 HbA1c has been reported to be an independent risk factor in development and
28
29 progression of DR in former studies ^{18,21}, while there existed little evidence on PBG in
30
31 DR progression. HbA1c was long considered to represent the management condition
32
33 of blood glucose, and bad glucose management contributed to the occurrence and
34
35 progression of DR ^{9,10,11}. PBG was reported to be abnormal in 31% DM patients
36
37 whose FBG was normal ⁴⁰, so it was considered an important diagnostic factor for DM.
38
39 PBG was more valuable in prediction of ischemic and hemorrhagic stroke,
40
41 cardiovascular disease mortality, while FBG was weak in prediction ^{41,42}. Therefore,
42
43 we thought that it was reasonable PBG was a risk factor for severe complications of
44
45 DM, such as DR. Possible mechanism of PBG in progression of DR might be that
46
47 PBG reflected capacity of insulin secretion, the peak of which was shown to be
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 delayed in type 2 DM⁴³. High level of PBG indicated that insulin secretion was
5
6 relatively insufficient which might result in a blood glucose fluctuation after food intake,
7
8 which did more harm to targeted organs. Our study firstly found that FBG was an
9
10 independent risk factor for STDR, meanwhile we also admit that OR was only 1.043
11
12 for 1 unit increase in FBG, which had limited meaning in predicting incidence of STDR.
13
14 No existed studies showed that FBG was an independent risk factor for DR, which
15
16 might be caused by a higher predictive value of HbA1c in these studies, and possible
17
18 mechanism of FBG for STDR required further studies. LDL and triglyceride were also
19
20 independent risk factors for DR, which indicated that management of blood lipids were
21
22 very important for DR prevention, while it had limited meanings for STDR compared
23
24 with other risk factors.
25
26
27
28
29

30
31 Our study also had some limitations. Firstly, due to limitations of device and screening
32
33 environment, several variables were incomplete and if we meant to analyze all
34
35 variables in this study, lots of data would be abandoned, and the result of multivariate
36
37 regression may be influenced. Secondly, although we tried to balance the resources
38
39 of patients, from north and south, from urban and rural areas, patients enrolled in final
40
41 all-factor logistic regression were not fully balanced due to the exclusion of missing
42
43 data. Thirdly, patients and screening clinics were not stratified sampled, and could not
44
45 fully represent the patient in mainland China. Fourthly, our study design was
46
47 cross-sectional, compared to cohort studies, cross-sectional studies had weaker
48
49 strength of evidence, and the results should be carefully explained. More cohort
50
51 studies focusing on several areas of China were required.
52
53
54
55
56
57
58
59
60

Conclusions

Our study demonstrated that age, diabetes duration and SBP were independent risk factors for both DR and STDR. PBG, HbA1c, Triglyceride and LDL were independent risk factors only for DR, and FBG only for STDR. This result was similar to existed studies and may provide some evidence on clinical prevention of DR and STDR, especially we firstly brought up that FBG, PBG, HbA1c were all important predictors for occurrence or progression of DR, and this required a stricter glucose control. More DR screening and information collection were required, which may decrease the incidence of DR and improve clinical results.

Acknowledgements:

Ownership of the program:

Chinese Foundation for Lifeline Express and Lifeline Express Hong Kong Foundation.

Funding/Support:

This study was also supported by Beijing Municipal Science & Technology Commission. Grant Number: Z141107002514042

Conflicts of interest: No potential conflicts of interest were reported.

Data sharing statement: No additional data are available.

Author Contributions: Y.L. and J.Y designed the whole study, completed the data collection, and wrote the manuscript. J.Y and L.T performed the data analysis and L.T contributed to the writing of the manuscript on epidemic part. H.L. and X.J. contributed to the study design, and contributed to the writing of the manuscript. M.Z. assisted

1
2
3
4 with the study design, data collection and contributed to the editing of the manuscript.
5
6 X.L. oversaw the study, gave advise on study design, and revised the manuscript. X.L.
7
8
9 is the guarantor of this study and had full access to all the data in this study, and X.L.
10
11 also takes responsibility for the integrity of the data and the accuracy of the data
12
13
14 analysis.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference:

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. *Diabetes Care*. 1998; 21: 1414-31.
2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. *Lancet Glob Health*. 2013;1(6):e339–49
3. Jones S, Edwards R T. Diabetic retinopathy screening: a systematic review of the economic evidence. *Diabet Med*. 2010, 27(3):249–256.
4. Heintz, E., Wiréhn, A.B., Peebo, B.B., et al. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. *Diabetologia*. 53(10), 2147–2154 (2010)
5. Moriya T, Tanaka S, Sone H, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. *J Diabetes Complications*. 2016 Jun 29. pii: S1056-8727(16)30224-0.
6. de Moraes G1, Layton CJ. Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy. *Clin Experiment Ophthalmol*. 2016 Jun 23.
7. Lim Y, Chun S, Lee JH, et al. Association of bone mineral density and diabetic retinopathy in diabetic subjects: the 2008-2011 Korea National Health and Nutrition Examination Survey. *Osteoporos Int*. 2016 Jul;27(7):2249-57.
8. Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study. *Ophthalmology*. 2013;120(3):574–82.

9. Knudsen L L, Lervang H H, Lundbye-Christensen S, et al. The North Jutland County Diabetic Retinopathy Study: population characteristics. *Br J Ophthalmol*. 2006, 90(11):1404-9.

10. Bertelsen G, Peto T, Lindekleiv H, et al. Tromsø eye study: prevalence and risk factors of diabetic retinopathy. *Acta Ophthalmol*, 2013, 91(8):716-21.

11. Dr. Xinzhi Zhang, Dr. Jinan B. Saaddine, Dr. Chiu-Fang Chou, et al. Prevalence of Diabetic Retinopathy in the United States, 2005–2008. *JAMA*. 2010, 304(6):649-656.

12. Piermarocchi R, Piermarocchi S, Tognetto D, et al. Prevalence of Diabetic Retinopathy and Its Risk Factors in the PAMDI Population of the Mediterranean Basin. *Eur J Ophthalmol*. 2015, 25(3).

13. George M, Harper R, Balamurugan A, et al. Diabetic retinopathy and its risk factors in a population-based study. *J Prim Care Community Health*. 2011, 2(2):122-126.

14. Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. *Ophthalmic Epidemiol*. 2010 Aug;17(4):251-65.

15. Dedov I, Maslova O, Suntsov Y, et al. Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. *Rev Diabet Stud*. 2009, 6(2):124-9.

16. Pugliese G, Solini A, Zoppini G, et al. High prevalence of advanced retinopathy in

1
2
3
4 patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events
5
6 (RIACE) Italian Multicenter Study. *Diabetes Res Clin Pract.* 2012, 98(2):329–337.
7

8
9 17. Villena J E, Yoshiyama C A, Sánchez J E, et al. Prevalence of diabetic retinopathy
10
11 in Peruvian patients with type 2 diabetes: results of a hospital-based retinal
12
13 telescreening program. *Rev Panam Salud Publica.* 2011, 30(5):408-14.
14

15
16 18. Esteves J F, Kramer C K, Azevedo M J, et al. Prevalence of diabetic retinopathy in
17
18 patients with type 1 diabetes mellitus. *Rev Assoc Med Bras.* 2009, 55(3):268-73.
19

20
21 19. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, et al. Ten-year
22
23 incidence of diabetic retinopathy and macular edema. Risk factors in a sample of
24
25 people with type 1 diabetes. *Diabetes Res Clin Pract.* 2011, 94(1):126-32.
26
27

28
29 20. Kajiwara A, Miyagawa H, Saruwatari J, et al. Gender differences in the incidence
30
31 and progression of diabetic retinopathy among Japanese patients with type 2
32
33 diabetes mellitus: A clinic-based retrospective longitudinal study. *Diabetes Res Clin*
34
35 *Pract.* 2014, 103(3):7-10.
36
37

38
39 21. Tam V H, Lam E P, Chu B C, et al. Incidence and progression of diabetic
40
41 retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. *J Diabetes*
42
43 *Complications.* 2008, 23(3):185-93.
44
45

46
47 22. Henricsson M, Nyström L, Blohmé G, et al. The incidence of retinopathy 10 years
48
49 after diagnosis in young adult people with diabetes: results from the nationwide
50
51 population-based Diabetes Incidence Study in Sweden (DISS). *Diabetes Care.* 2003,
52
53 26(2):349-354.
54
55

56
57 23. Stratton I M, Kohner E M, Aldington S J, et al. UKPDS 50: Risk factors for
58
59
60

1
2
3
4 incidence and progression, of retinopathy in Type II diabetes over 6 years from
5
6 diagnosis. *Diabetologia*. 2001, 44(2):156-63.
7

8
9 24. Salinerofort M Á, Burgoslunar C D, Arrietablanco F J, et al. Four-Year Incidence of
10
11 Diabetic Retinopathy in a Spanish Cohort: The MADIABETES Study. *PLoS One*.
12
13 2012, 8(8):377-380.
14

15
16 25. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence
17
18 of diabetic retinopathy. The Beijing Eye Study 2001/2011. *PLoS One*.
19
20 2014;9(10):e1111320.
21
22

23
24 26. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of
25
26 diabetic retinopathy during 17 years of a population-based screening program in
27
28 England. *Diabetes Care*. 2012;35(3):592–6.
29

30
31 27. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS
32
33 report number 12. Early Treatment Diabetic Retinopathy Study Research Group.
34
35 *Ophthalmology*. 1991;98(5 Suppl):823–33.
36
37

38
39 28. Yan ZP, Ma JX. Risk factors for diabetic retinopathy in northern Chinese patients
40
41 with type 2 diabetes mellitus. *Int J Ophthalmol*. 2016 Aug 18;9(8):1194-9.
42

43
44 29. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic
45
46 macular edema and related vision loss. *Eye Vis (Lond)*. 2015 Sep 30;2:17.
47

48
49 30. Zhou M, Astell-Burt T, Bi Y, et al. Geographical variation in diabetes prevalence
50
51 and detection in china: multilevel spatial analysis of 98,058 adults. *Diabetes Care*.
52
53 2015;38(1):72-81.
54

55
56 31. Liu Y, Song Y, Tao L, et al. Prevalence of diabetic retinopathy among
57
58
59
60

1
2
3
4 13473 patients with diabetes mellitus in China: a cross sectional epidemiological survey
5
6 in six provinces. *BMJ Open* 2017;7:e013199.

7
8
9 32. Harding S, Greenwood R, Aldington S, et al. Grading and disease management in
10 national screening for diabetic retinopathy in England and Wales. *Diabet Med*.
11 2003;20(12):965-971.

12
13
14 33. BCGuidelines.ca: Hypertension – Diagnosis and Management (2015). Available
15 at: www.bcguidelines.ca

16
17 34. Mansfield ER, Helms BP. Detecting multicollinearity. *Am Stat*. 1982;36(3):158–60.

18
19
20 35. Semeraro F, Parrinello G, Cancarini A, Pasquini L, Zarra E, Cimino A, Cancarini G,
21 Valentini U, Costagliola C. Predicting the risk of diabetic retinopathy in type 2 diabetic
22 patients. *J Diabetes Complications*. 2011 Sep-Oct;25(5):292-7.

23
24
25 36. Nakamura M, Barber AJ, Antonetti DA, LaNoue KF, Robinson KA, et al. Excessive
26 hexosamines block the neuroprotective effect of insulin and induce apoptosis in
27 retinal neurons. *J Biol Chem*. 2011;276: 43748–43755

28
29
30 37. Juutilainen A, Lehto S, Ronnema T, Pyorala K, Laakso M: Retinopathy predicts
31 cardiovascular mortality in type 2 diabetic men and women. *Diabetes Care*.
32 2007;30:292–299.

33
34
35 38. Fauziana R, Jeyagurunathan A, Abdin E. Body mass index, waist-hip ratio and
36 risk of chronic medical condition in the elderly population: results from the Well-being
37 of the Singapore Elderly (WiSE) Study. *BMC Geriatr*. 2016 Jun 18;16(1):125.

38
39
40 39. Man RE1, Sabanayagam C2, Chiang PP. Differential Association of Generalized
41 and Abdominal Obesity With Diabetic Retinopathy in Asian Patients With Type 2
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diabetes. *JAMA Ophthalmol.* 2016 Mar 1;134(3):251-7.

40. Eriksson J, Jousilahti P, Lindström J, et al. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. *Diabetologia*, 1999;Jun;42(6):647-54.

41. Hyvärinen M, Tuomilehto J, Mähönen M. Hyperglycemia and incidence of ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose criteria. *Stroke.* 2009 May;40(5):1633-7.

42. Ning F1, Tuomilehto J, Pyörälä K. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. *Diabetes Care.* 2010 Oct;33(10):2211-6.

43. Guillausseau PJ, Meas T, Virally M. Abnormalities in insulin secretion in type 2 diabetes mellitus. *Diabetes Metab.* 2008 Feb;34 Suppl 2:S43-8.

Figure legends.

Figure 1 Flow diagram of the data processing.

Figure 2 Nomograms for DR (A) and STDR (B) risk factors. Risk factors were chosen based on results of logistic regression analysis. Each risk factor of the patient was assessed on basis of the nomogram and got a point by vertically corresponding to the first line Aggregated points of each risk factor corresponded to a particular occurrence probability of DR or STDR in the last line.

Table 1—Univariate analysis of DR risk factors. (N=12733)

Variable	n	No DR (n=8772)	n	DR (n=3961)	P	OR	95%CI
Male gender, n(%)	8772	3985(45.4%)	3961	1851(46.7%)	0.172		
Age, years(SD)	8770	63.0(10.3)	3959	61.0(9.8)	<0.001		
<30, %	11	30.6%	25	69.4%			
30-40, % (vs.<30)	143	66.8%	71	33.2%	0.757	1.128	0.526-2.423
40-50, % (vs.30-40)	733	64.2%	408	35.8%	0.469	1.121	0.823-1.527
50-60, % (vs.40-50)	2138	63.2%	1243	36.8%	0.542	1.004	0.908-1.201
60-70, % (vs.50-60)	3443	69.7%	1494	30.3%	<0.001	0.746	0.680-0.819
>70, % (vs.60-70)	2217	76.0%	700	24.0%	<0.001	0.728	0.655-0.808
Diagnosis age, years (SD)	8770	56.3 (10.2)	3959	50.8 (10.3)	<0.001		
Diabetes duration, years (SD)	8772	6.7 (5.9)	3961	10.2 (6.8)	<0.001		
<5, %	4692	80.0%	1174	20.0%			
5-10, % (vs. <5)	2314	65.7%	1208	34.3%	<0.001	2.086	1.898-2.293
10-15, % (vs. 5-10)	1032	57.6%	761	42.4%	<0.001	1.413	1.257-1.587
15-20, % (vs. 10-15)	521	48.2%	560	51.8%	<0.001	1.458	1.252-1.696
>20, % (vs. 15-20)	213	45.2%	258	54.8%	0.281	1.127	0.907-1.400
BMI (SD)	6000	24.7 (3.5)	2854	24.9 (3.9)	0.116		
Underweight, %	97	64.7%	53	35.3%			
Normal weight, % (vs. underweight)	3348	68.5%	1543	31.5%	0.326	0.843	0.600-1.185
Overweight, % (vs. normal weight)	2175	67.6%	1043	32.4%	0.414	1.041	0.946-1.145
Obese, % (vs. overweight)	380	63.9%	215	36.1%	0.076	1.180	0.983-1.417
SBP, mmHg (SD)	8762	133.3 (16.5)	3952	137.0(17.9)	<0.001		
DBP, mmHg (SD)	8762	79.6 (9.9)	3952	80.8 (10.8)	<0.001		
Normal BP, %	5084	72.3%	1950	27.7%			
BP level 1, % (vs. normal)	2840	66.7%	1420	33.3%	<0.001	1.303	1.200-1.414
BP level 2, % (vs. level 1)	665	59.3%	456	40.7%	<0.001	1.371	1.198-1.569
BP level 3, % (vs. level 2)	173	57.9%	126	42.1%	0.648	1.062	0.820-1.376
Waistline, cm (SD)	5719	89.3 (10.1)	2735	90.3 (10.6)	<0.001		
Hipline, cm (SD)	5719	96.6 (9.7)	2735	97.1 (9.5)	0.028		
WHR (SD)	5719	0.926 (0.074)	2735	0.930 (0.069)	0.007		
Abdominal obesity, n(%)		4677 (81.8%)		2267 (82.9%)	0.213	1.079	0.957-1.217
Female (SD)	3152	0.915 (0.076)	1501	0.923 (0.072)	0.002		
Male (SD)	2567	0.94 (0.070)	1234	0.94 (0.064)	0.674		
Medicine	5793		2797		<0.001		

No medicine, %	660	87.0%	99	13.0%			
Oral medicine, % (vs. no medicine)	3296	73.2%	1208	26.8%	<0.001	5.407	4.331-6.752
Insulin, % (vs. oral medicine)	1837	55.2%	1490	44.8%	<0.001	2.213	2.013-2.434
FBG, mmol/L (SD)	7547	7.8 (2.4)	3517	8.7 (3.0)	<0.001		
PBG, mmol/L (SD)	4780	10.7 (3.3)	2095	11.8 (3.5)	<0.001		
HbA1c, % (SD)	7762	7.16 (1.65)	3146	7.82 (1.90)	<0.001		
BUN, mmol/L (SD)	6357	5.79 (8.19)	2633	6.33 (10.51)	0.01		
Cr, µmol/L (SD)	6320	76.5 (112.7)	2615	78.8 (39.2)	0.328		
Cholesterol, mmol/L (SD)	6418	5.04 (2.69)	2651	5.06 (1.31)	0.752		
Triglyceride, mmol/L (SD)	6382	1.87 (1.22)	2635	1.89 (1.26)	0.456		
HDL, mmol/L (SD)	6392	1.37 (0.56)	2642	1.38 (0.57)	0.481		
LDL, mmol/L (SD)	6399	2.72 (1.00)	2643	2.83 (1.00)	<0.001		

Continuous variables were reported as mean value and standard deviation, and categorical variables were reported as percentage, OR and 95% CI. P<0.05 was considered statistically significant and marked in bold. n, number; OR, odd ratio; 95%CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist hip ratio; FBG, fasting blood glucose; PBG, postprandial blood glucose; HbA1c, glycosylated hemoglobin; BUN, blood urea nitrogen; Cr, creatinine; HDL, high density lipoprotein; LDL, low density lipoprotein.

Table 2—Univariate analysis of STDR risk factors. (N=12621)

Variable	n	None-STDR (n=10875)	n	STDR (n=1746)	P	OR	95%CI
Male gender, n(%)	10875	4985 (45.8%)	1746	799 (45.8%)	0.952		
Age, years (SD)	10873	62.7 (10.2)	1745	60.4 (9.7)	<0.001		
<30, %	32	88.9%	4	11.1%			
30-40, % (vs.<30)	181	85.0%	32	15.0%	0.757	1.128	0.526-2.423
40-50, % (vs.30-40)	927	81.9%	205	18.1%	0.469	1.121	0.823-1.527
50-60, % (vs.40-50)	2785	82.9%	576	17.1%	0.542	1.004	0.908-1.201
60-70, % (vs.50-60)	4253	86.9%	643	13.1%	<0.001	0.746	0.680-0.819
>70, % (vs.60-70)	2160	88.9%	270	11.1%	<0.001	0.728	0.655-0.808
Diagnosis age, years (SD)	10873	55.4 (10.4)	1745	49.4 (10.4)	<0.001		
Diabetes duration, years (SD)	10875	7.2 (6.2)	1746	11.0 (6.8)	<0.001		
<5, %	4692	80.0%	1174	20.0%			
5-10, % (vs. <5)	2314	65.7%	1208	34.3%	<0.001	2.086	1.898-2.293
10-15, % (vs. 5-10)	1032	57.6%	761	42.4%	<0.001	1.413	1.257-1.587
15-20, % (vs. 10-15)	521	48.2%	560	51.8%	<0.001	1.458	1.252-1.696
>20, % (vs. 15-20)	213	45.2%	258	54.8%	0.281	1.127	0.907-1.400
BMI (SD)	7518	24.8 (3.6)	1256	24.8 (3.9)	0.738		
Underweight	120	81.1%	28	18.9%			
Normal weight, % (vs. underweight)	4145	85.5%	703	14.5%	0.134	0.727	0.478-1.105
Overweight, % (vs. normal weight)	2759	86.6%	428	13.4%	0.177	0.915	0.804-1.041
Obese, % (vs. overweight)	494	83.6%	97	16.4%	0.054	1.266	0.995-1.610
SBP, mmHg (SD)	10863	133.8 (16.7)	1741	138.1 (18.7)	<0.001		
DBP, mmHg (SD)	10863	79.8 (10.0)	1741	81.0 (11.4)	<0.001		
Normal BP, %	6164	88.2%	826	11.8%			
BP level 1, % (vs. normal BP)	3584	85.0%	630	15.0%	<0.001	1.312	1.173-1.467
BP level 2, % (vs. BP level 1)	892	80.5%	216	19.5%	<0.001	1.378	1.161-1.635
BP level 3, % (vs. BP level 2)	223	76.4%	69	23.6%	0.118	1.278	0.939-1.739
Waistline, cm(SD)	7176	89.4 (10.1)	1200	90.7 (10.8)	<0.001		
Hipline, cm(SD)	7176	96.7 (9.6)	1200	97.2 (10.1)	0.120		
WHR (SD)	7176	0.926 (0.073)	1200	0.934(0.071)	0.001		
Abdominal obesity,n(%)		5872(81.8%)		1004(83.7%)	0.124	1.113	0.970-1.276
Female (SD)	3947	0.92 (0.075)	666	0.93 (0.074)	<0.001		

1								
2								
3	Male (SD)	3229	0.94 (0.069)	534	0.94 (0.065)	0.634		
4	Medicine	7304		1218		<0.001		
5	No medicine, %	727	93.7%	49	6.3%			
6	Oral medicine, %	4008	89.6%	465	10.4%	<0.001	2.908	1.982-4.267
7	(vs. no medicine)							
8	Insulin, %	2569	78.0%	724	22.0%	<0.001	2.429	2.140-2.757
9	(vs. oral medicine)							
10	FBG, mmol/L (SD)	9451	8.0 (2.5)	1521	8.9 (3.1)	<0.001		
11	PBG, mmol/L (SD)	5964	10.9 (3.3)	886	11.9 (3.6)	<0.001		
12	HbA1c, % (SD)	9548	7.25 (1.70)	1280	8.05 (1.97)	<0.001		
13	BUN, mmol/L (SD)	7855	5.89 (9.38)	1072	6.38 (4.99)	0.092		
14	Cr, µmol/L (SD)	7812	76.2 (102.1)	1060	84.2 (52.3)	0.012		
15	Cholesterol, mmol/L (SD)	7927	5.05 (2.48)	1079	5.06 (1.29)	0.904		
16	Triglyceride, mmol/L (SD)	7884	1.87 (1.22)	1072	1.94 (1.29)	0.072		
17	HDL, mmol/L (SD)	7897	1.37 (0.56)	1074	1.38 (0.54)	0.755		
18	LDL, mmol/L (SD)	7907	2.74 (0.99)	1072	2.82 (1.06)	0.015		
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								
31								
32								
33								
34								
35								
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								
47								
48								
49								
50								
51								
52								
53								
54								
55								
56								
57								
58								
59								
60								

Table 3 —Logistic regression of DR and STDR risk factors. (Both in eight-factor analysis and all-factor analysis.)

Variable	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
	DR risk factors analysis						STDR risk factors analysis					
	eight-factor analysis (N=9367)			all-factor analysis (N=4623)			eight-factor analysis (N=9303)			all-factor analysis (N=4597)		
Sex (women vs men)	1.026	0.932-1.130	0.169	1.052	0.913-1.213	0.489	0.979	0.855-1.120	0.753	1.176	0.960-1.442	0.118
Age	0.966	0.961-0.971	<0.001	0.968	0.961-0.976	<0.001	0.961	0.954-0.968	<0.001	0.961	0.950-0.972	<0.001
Diabetes duration	1.102	1.093-1.111	<0.001	1.071	1.059-1.084	<0.001	1.102	1.091-1.113	<0.001	1.077	1.061-1.094	<0.001
SBP	1.015	1.011-1.018	<0.001	1.016	1.010-1.021	<0.001	1.017	1.011-1.021	<0.001	1.017	1.010-1.024	<0.001
DBP	0.995	0.989-1.001	0.083	0.994	0.986-1.002	0.152	0.987	0.980-0.995	0.002	0.990	0.979-1.002	0.095
FBG	1.040	1.019-1.062	<0.001	1.008	0.972-1.046	0.666	1.043	1.016-1.071	0.002	1.076	1.028-1.127	0.002
HbA1c	1.164	1.128-1.201	<0.001	1.102	1.051-1.156	<0.001	1.168	1.172-1.250	<0.001	1.060	0.994-1.130	0.077
PBG				1.039	1.014-1.065	0.003				1.013	0.979-1.048	0.473
BMI				0.991	0.972-1.012	0.406				0.976	0.948-1.005	0.109
WHR				1.527	0.591-3.947	0.382				3.314	0.927-11.842	0.065
Medicine												
Oral vs. no medicine				2.158	1.517-3.069	<0.001				3.737	1.721-8.113	0.001
Insulin vs. no medicine				3.535	2.455-5.089	<0.001				6.856	3.141-14.966	<0.001
BUN				1.004	0.997-1.011	0.238				1.002	0.994-1.010	0.598
Cr				1.000	1.000-1.001	0.745				1.000	1.000-1.001	0.121
Cholesterol				0.999	0.955-1.044	0.948				0.995	0.924-1.071	0.890
Triglyceride				0.924	0.873-0.979	0.007				0.950	0.878-1.028	0.200

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

HDL	1.030	0.901-1.176	0.668	0.970	0.789-1.193	0.776
LDL	1.099	1.017-1.187	0.017	1.093	0.978-1.221	0.118

P<0.05 was considered statistically significant and marked in bold.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of the data processing.

163x151mm (300 x 300 DPI)

only




Figure 2 Nomograms for DR (A) and STDR (B) risk factors.

Risk factors were chosen based on results of logistic regression analysis. Each risk factor of the patient was assessed on basis of the nomogram and got a point by vertically corresponding to the first line Aggregated points of each risk factor corresponded to a particular occurrence probability of DR or STDR in the last line.

172x85mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4, 5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	23
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	25-26
		(b) Indicate number of participants with missing data for each variable of interest	25-26
Outcome data	15*	Report numbers of outcome events or summary measures	25-26
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	25-26
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risk Factors of Diabetic Retinopathy and Sight-threatening Diabetic Retinopathy: A Cross-sectional Study of 13473 Patients with Type 2 Diabetes Mellitus in Mainland China.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016280.R2
Article Type:	Research
Date Submitted by the Author:	01-Aug-2017
Complete List of Authors:	Liu, Yan; Peking University Third Hospital, Department of Ophthalmology Yang, Jiarui; Peking University Third Hospital, Department of Ophthalmology Tao, Liyuan; Peking University Third Hospital, Research Center of Clinical Epidemiology Lv, Hui bin; Peking University Third Hospital, Department of Ophthalmology Jiang, Xiaodan; Peking University Third Hospital, Department of Ophthalmology Zhang, Mingzhou; Peking University Third Hospital, Department of Ophthalmology Li, Xuemin; Peking University Third Hospital, Department of Ophthalmology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology, Medical management
Keywords:	Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, risk factor, blood glucose, WHR, BMI

SCHOLARONE™
Manuscripts

1
2
3
4 Title: Risk Factors of Diabetic Retinopathy and Sight-threatening Diabetic Retinopathy:
5
6 A Cross-sectional Study of 13473 Patients with Type 2 Diabetes Mellitus in Mainland
7
8 China.
9

10
11 Running title: Risk factors of DR and STDR in China
12

13
14 Authors: Yan Liu MD^{1*}, Jiarui Yang MD^{1*}, Liyuan Tao PhD², Huibin Lv MD¹, Xiaodan
15
16 Jiang MD¹, Mingzhou Zhang MD¹, Xuemin Li MD¹
17

18
19 * These authors contributed equally to this work.
20

21
22 1 Department of Ophthalmology, Peking University Third Hospital
23

24
25 2 Research Center of Clinical Epidemiology, Peking University Third Hospital
26

27
28 Corresponding author: Xuemin Li MD
29

30
31 Address: Department of Ophthalmology, Peking University Third Hospital,
32

33
34 No.49Huayuan North Street, Haidian District, Beijing, China
35

36
37 Email: 13911254862@163.com; lxm1xm66@sina.com.cn
38

39
40 Word count: 3562 words
41

42
43 Number of figures: 2.
44

45
46 Number of tables: 3.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Risk Factors of Diabetic Retinopathy and Sight-threatening Diabetic**
5
6 **Retinopathy: A Cross-sectional Study of 13473 Patients with Type 2 Diabetes**
7
8 **Mellitus in Mainland China**
9

10
11 **Abstract:**
12

13
14 **Objective:** To explore the risk factors of diabetic retinopathy (DR) and
15
16 sight-threatening diabetic retinopathy (STDR) among Chinese patients with diabetes.
17

18
19 **Design, setting and participants:** A cross-sectional investigation was performed in
20
21 eight screening clinics in six provinces across mainland China. Information about the
22
23 risk factors was recorded in screening clinics. Some risk factors (sex, age, diagnosis
24
25 age, diabetes duration, SBP, DBP, FBG, HbA1c) were recorded in all eight clinics,
26
27 while others were collected only in a subset of the clinics. The relationships between
28
29 the risk factors and DR and between the risk factors and STDR were explored for the
30
31 eight factors mentioned above and for all factors studied.
32
33
34

35
36 **Main outcomes and measures:** Risk factors of DR and STDR were assessed, and a
37
38 nomogram of the results was produced.
39

40
41 **Results:** Younger age, longer diabetes duration, higher SBP, higher FBG, and higher
42
43 HbA1c were found to be independent risk factors for both DR and STDR in the
44
45 eight-factor analyses. In the all-factor analysis, younger age, longer diabetes duration,
46
47 higher SBP, oral medicine use, and insulin use were independent risk factors for both
48
49 DR and STDR; higher PBG, HbA1c, triglyceride and LDL were independent risk
50
51 factors for DR only, and higher FBG was a risk factor for STDR only.
52
53
54

55
56 **Conclusions:** In this cross-sectional investigation, several risk factors were found for
57
58
59
60

1
2
3
4 DR and STDR. Notably, FBG, PBG and HbA1c were all risk factors for DR or STDR,
5
6 suggesting that stricter blood glucose control in clinical practice is required.
7
8

9 **Key words:** diabetic retinopathy, risk factors, glucose, WHR, BMI
10

11 **Strengths and limitations of this study**

- 12 ● This is a cross-sectional population-based (13473 subjects) investigation of the
13 risk factors for diabetic retinopathy
14
- 15 ● The study was performed in eight hospitals from 6 different provinces in mainland
16 China, and participants were from hospitals and communities that included rural
17 and urban regions.
18
- 19 ● We separately analysed the risk factors for diabetic retinopathy (DR) and
20 sight-threatening diabetic retinopathy (STDR), both of which have implications for
21 clinical practice.
22
- 23 ● Owing to the multi-centre design, some information was not comprehensively
24 collected, which resulted in an imperfect risk factor analysis.
25
- 26 ● The sampling method of this study was not stratified, which might result in a lack
27 of representativeness.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Diabetes Mellitus (DM) is a metabolic syndrome with an increasing prevalence and high mortality rate¹. Diabetic retinopathy (DR) is a common ocular complication of DM and is considered to be one of the leading causes of vision loss and vision impairment in adults². With the progression of DR, the quality of life of patients decreases, and the financial burden on society increases, both in the DR screening and treatment groups^{3,4}.

DR has been considered to be correlated with many other diabetes-related complications, such as nephropathy, peripheral neuropathy, low bone density and cardiovascular events, all of which lower the quality of life and produce a high rate of mortality⁵⁻⁸. Therefore, early diagnosis and proper management of DR would be of great significance.

Many epidemiologic studies on DR, either cross-sectional studies⁹⁻¹⁸ or cohort studies¹⁹⁻²⁸, have been conducted worldwide, exploring the risk factors that were associated with the disease and aiming at the prevention and management of this disease. Older female patients with a longer disease duration were known to be at greater risk for DR and DR progression. Furthermore, having renal complications of diabetes, poor glycaemic control, high lipid levels, or hypertension have also already been reported to be risk factors of DR, with an impact on DR progression⁹⁻²⁶. These factors have been evaluated using the Treatment of Diabetic Retinopathy Study (ETDRS) classification²⁷. Of these reported risk factors, the duration of diabetes,

1
2
3
4 hyperglycaemia and hypertension were considered to be the most important risk
5
6 factors for progression of vision loss²⁹. However, DR and the risk factors of DR have
7
8 typically gained little attention, and the compliance with eye screenings is often poor³⁰.
9
10 More studies and an improved awareness of the risk factors are therefore required.
11
12 In China, a few DR screening studies have been conducted, but most have been
13
14 completed only in a limited area^{21,25,28}. Therefore, a cross-sectional investigation in 6
15
16 provinces (including the northern and southern parts of China) was conducted. The
17
18 prevalence of DR and its basic epidemiological characteristics have been reported in
19
20 a previously published article³¹. In this study, we sought to explore the risk factors
21
22 associated with DR and STDR in mainland China.
23
24
25
26
27

28 **METHODS**

29 **Research design**

30
31
32 The Lifeline Express Diabetic Retinopathy Screening Program was conducted
33
34 nationwide, and it involved a cross-sectional investigation in eight hospitals from 6
35
36 different provinces (Shandong, Henan, Inner Mongolia, Jilin, Guangxi, Guangdong
37
38 Provinces). Subjects were recruited from hospitals and local communities (1/3 from
39
40 hospital patients, 1/3 from city residents, and the other 1/3 from rural residents)
41
42 between April 2014 and October 2015. The study protocol was approved by the
43
44 Peking University Third Hospital Ethics Committee, and written informed consent was
45
46 obtained for each subject. The study was performed in accordance with the
47
48 Declaration of Helsinki.
49
50
51
52
53
54
55
56
57

58 In the hospital, subjects were diagnosed with DM by qualified physicians and
59
60

1
2
3 transferred to eight screening clinics. In the community, subjects were recruited by
4
5 advertisement, and medical records of a DM diagnosis were required when they
6
7 visited the screening clinics. Of all the screening clinics, 3 were in the south and 5
8
9 were in the north of China. All subjects received a digital, colourful and
10
11 non-stereoscopic retinography, which was taken by a non-mydratic auto fundus
12
13 camera. The photograph included 2 fields for each eye: one centred at the optic disc
14
15 and the other centred at the macula.
16
17
18
19

20 21 22 **DR/STDR diagnosis and grading:**

23
24 DR was graded by trained and certified optometrists and ophthalmologists at the
25
26 Lifeline Express Diabetic Retinopathy Central Assurance Centre. All of the graders
27
28 underwent periodic tests to ensure the accuracy of their grading. Retinopathy was
29
30 graded according to fundus photographs of two eyes into no DR(R0) and DR (other
31
32 stages), and DR was also graded as none sight-threatening diabetic retinopathy
33
34 (non-STDR) or sight-threatening diabetic retinopathy (STDR) according to the UK
35
36 guidelines³². Non-STDR was recognized as R0 and R1, while STDR was identified as
37
38 present if any features of maculopathy (M1), pre-proliferative DR (R2) or PDR (R3)
39
40 were found. If the fundus photographs were ungradable because of missing data or
41
42 non-diagnostic images due to cataracts or vitreous opacities, the patients were
43
44 excluded from the risk factor analysis. If the photograph of one eye was unrecognized,
45
46 the final diagnosis was determined by the only remaining photograph. In this condition,
47
48 if the remaining photograph was graded R0, patients were excluded because of a lack
49
50 of evidence. If the remaining photograph was graded R1, patients were diagnosed as
51
52
53
54
55
56
57
58
59
60

1
2
3
4 DR and excluded from the STDR analysis, while if it was graded as M1, R2 or R3,
5
6 patients were diagnosed as DR and STDR.
7
8
9

10 **Information collection**

11
12 At the time of the clinical visit, the gender, age, diagnosis age, diabetes duration
13 (calculated from the age and onset age), diabetes type (as evaluated by physicians in
14 screening clinics), body mass index (BMI, calculated from the measured height and
15 weight), waist–hip ratio (WHR, calculated from the measured waistline and hipline),
16
17 and type of treatment were recorded. Systolic blood pressure(SBP), diastolic blood
18 pressure (DBP), fasting blood-glucose (FBG), postprandial blood glucose 2 hours
19 after eating 75 mg glucose (PBG) and glycosylated haemoglobin (HbA1c) were
20 measured at the screening clinics, and blood samples after fasting for 8 hours were
21 collected for cholesterol, triglyceride, high density lipoprotein (HDL), low density
22 lipoprotein (LDL), blood urea nitrogen (BUN), and serum creatinine (Cr)
23 measurements. Gender, age, diagnosis age, diabetes duration, blood pressure, FBG
24 and HbA1c were collected for each patient, while other information was limited to only
25 part of the subjects because of the environment and devices.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Statistical analysis**

50 Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago,
51 IL). The independent t-test was used to compare continuous variables, and the
52 chi-square test was used to compare discontinuous variables among the groups.
53
54 Owing to the limited number of type 1 and gestational diabetic patients, we analysed
55
56
57
58
59
60

1
2
3
4 the data from the type 2 diabetic patients only.

5
6 We first conducted a four-step analysis of the relationship between the risk factors
7
8 and DR. In the first step, the mean values and the median values of the main
9
10 variables were calculated. In the second step, univariate analyses of the associations
11
12 between the existence of DR and the risk factors were completed. In this step, several
13
14 continuous variables, including age, diabetes duration, blood pressure (BP), BMI, and
15
16 WHR were also transferred into categorical variables, to explore their detailed
17
18 relationship with DR. Age was divided into groups with 10-year intervals, and diabetes
19
20 duration was divided into groups with 5-year intervals. BP values were catalogues as
21
22 normal BP, level 1 hypertension, level 2 hypertension, and severe hypertension³³.
23
24 BMI was divided into underweight (<18.5), normal weight (≥ 18.5 & <24), overweight
25
26 (≥ 24 & <28) and obese (≥ 28) categories. WHR was divided into normal WHR (male
27
28 ≤ 0.90 & female ≤ 0.85) and abdominal obesity (male 0.90 & female ≤ 0.85) and was
29
30 also divided into male and female groups. In the third step, multicollinearity diagnosis
31
32 was performed, and a variance inflation factor (VIF) >10 was thought to have a high
33
34 collinearity³⁴. Furthermore, variables with high a collinearity were evaluated, and the
35
36 variable that was most relevant to the research purpose was determined by two
37
38 researchers (YJR and LY). In the fourth step, binary logistic regression analyses were
39
40 carried out, taking the existence of DR as the dependent variable and all risk factors,
41
42 which were significantly associated with the existence of DR in the former step or
43
44 considered to be important risk factors based on existing studies, as independent
45
46 variables. Owing to limitations in the information collection, we separately analysed
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 the eight risk factors that were completely collected in each screening clinic
5
6 (eight-factor analysis), and all risk factors (all-factor analysis); furthermore, the
7
8 differences between the two analyses were discussed.
9

10
11 Then, the relationship between the risk factors and STDR was also conducted in the
12
13 aforementioned way. Odds ratios (ORs) and 95% confidence intervals were
14
15 calculated. An α level of 0.05 was adopted as the significance level.
16
17

18
19 At last, nomograms for DR and STDR risk factors were developed, and significant risk
20
21 factors in former binary logistic regression were regarded as predictors. Interpretation
22
23 of the nomogram in the prediction of DR has been reported in former studies³⁵, which
24
25 included two major parts. In the first part, the exact values of each predictor were
26
27 vertically linked to a certain point (the first row of the nomogram), and the total points
28
29 of each predictor were calculated. In the second part, the total points were linked to a
30
31 specific risk incidence of DR and STDR (the last row of the nomogram), which has
32
33 implications for clinical practice.
34
35
36
37
38

39 **Results**

40
41 From April 2014 to October 2015, 13473 DM patients from 6 provinces were enrolled
42
43 in the study. 45.9% patients were from the southern provinces (6180/13473) and 54.1%
44
45 were from the northern provinces (7293/13473). Of all the patients, 13304 patients
46
47 were diagnosed with type 2 diabetes, 96 were diagnosed with type 1 diabetes, and 73
48
49 were diagnosed with gestational diabetes. Patients were divided into a no DR and a
50
51 DR group and a non-STDR and a STDR group, according to the fundus photograph
52
53 grading. 571 patients were excluded from the DR risk factor analysis, and 683
54
55
56
57
58
59
60

1
2
3
4 patients were excluded from the STDR risk factor analysis because of the diagnostic
5
6 rules mentioned above. Finally, 12733 patients were included in the DR risk factor
7
8 analysis and 12621 patients were included in the STDR risk factor analysis (shown in
9
10 Figure 1).
11

12
13
14 First, analyses of the DR risk factors were performed, and the basic characteristics of
15
16 all risk factors are shown in Table 1. The results of the univariate analyses indicated
17
18 that the age, diagnosis age, diabetes duration, SBP, DBP, waistline, hipline, WHR,
19
20 medicine type (oral medication or insulin injection), FBG, PBG, HbA1c, BUN, and LDL
21
22 were statistically significantly different between the groups ($p < 0.05$), and no significant
23
24 difference was found in the gender, BMI, Cr, cholesterol, triglyceride, and HDL
25
26 ($p > 0.05$).
27
28
29

30
31 Furthermore, our categorical analyses showed that patients were getting less likely to
32
33 suffer from DR every 10 years after 60 years of age, while no difference was found
34
35 before age 60. The incidence of DR increased significantly for every 5 years of
36
37 diabetes duration but stopped increasing after 20 years of diabetes duration. The
38
39 results of the blood pressure analysis indicated that diabetes incidence increased with
40
41 increases in the blood pressure, although diabetes incidence did not differ between
42
43 level 3 BP and level 2 BP. Females had a higher WHR in DR, while males did not, and
44
45 the condition of abdominal obesity did not influence the incidence of DR.
46
47
48

49
50 Then, multivariate analyses were performed. Multicollinearity diagnosis was
51
52 performed in both the eight-factor analysis and all-factor analysis. The results
53
54 excluded the diagnosis age (highly correlated to the age and DR duration) in the
55
56
57
58
59
60

1
2
3
4 eight-factor analysis and excluded the diagnosis age (highly correlated to age and DR
5
6 duration), waistline, and hipline (both of which were highly correlated to WHR) in the
7
8 all-factor analysis because of the high collinearity. Multiple logistic regression
9
10 analyses were carried out, and the results are shown with the STDR analysis. The
11
12 results of eight-factor analysis (with the diagnosis age excluded) showed that younger
13
14 age, longer diabetes duration, higher SBP, higher FBG, and higher HbA1c were
15
16 independent risk factors for DR ($p < 0.05$), and sex and DBP were not significantly
17
18 associated with DR ($p > 0.05$). A multiple logistic regression of the all-factor analysis
19
20 (with diagnosis age, waistline, and hipline excluded) was also conducted, and the
21
22 results showed that younger age, longer diabetes duration, higher SBP, HbA1c, PBG,
23
24 oral medicine, insulin use, higher triglyceride, and higher LDL were the independent
25
26 risk factors for DR ($p < 0.05$), while sex, DBP, BMI, FBG, WHR, BUN, Cr, cholesterol,
27
28 and HDL were not associated with DR ($p > 0.05$).

29
30 After the DR risk factors analyses, analyses of the STDR risk factors were conducted,
31
32 and characteristics of the risk factors are shown in Table 2. Age, diagnosis age,
33
34 diabetes duration, SBP, DBP, HbA1c, FBG, PBG, waistline, WHR, medicine, Cr, and
35
36 LDL showed statistically significant differences between groups ($p < 0.05$), while
37
38 gender, BMI, hipline, BUN, cholesterol, triglyceride, and HDL were not significantly
39
40 different. After a multicollinearity diagnosis, the diagnosis age was excluded in the
41
42 eight-factor analysis. The diagnosis age, waistline and hipline were excluded in the
43
44 all-factor analysis. The results of multiple logistic regressions of STDR analyses
45
46 (together with DR analyses) are shown in Table 3. The results of the eight-factor
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 analysis (with the diagnosis age dropped) showed that younger age, longer diabetes
5
6 duration, higher SBP, DBP, FBG, and HbA1c were independent risk factors for STDR
7
8 (p<0.05), and sex was not significantly associated with STDR (p>0.05). The results of
9
10 the all-factor analysis indicated that a younger age, longer diabetes duration, higher
11
12 SBP, higher FBG, oral medicine use and insulin use were regarded as independent
13
14 risk factors for STDR (p<0.05), while other risk factors showed no significant
15
16 differences (p>0.05).
17
18
19

20
21 Furthermore, we subcategorized the non-STDR group into the non-DR and DR but not
22
23 STDR groups, and the risk factors between the DR but not STDR group and the non-DR,
24
25 STDR or DR group. The results showed that independent risk factors for DR but not
26
27 STDR compared with non-DR were exactly the same as for DR/no DR. However, the risk
28
29 factors of the STDR compared to DR but not STDR analysis showed two new
30
31 independent risk factors in addition to those for STDR/non-STDR, which were male
32
33 sex and Cr.
34
35
36
37

38
39 Finally, we developed a nomogram to simplify the presentation and understanding of
40
41 our results (Figure 2).
42
43

44 **Discussion**

45
46 Based on the results of our study, we tried to find a reasonable explanation and an
47
48 internal relationship between DR, STDR and risk factors.
49

50
51 First, focusing on the univariate analysis, 14 out of 20 risk factors were found to be
52
53 significantly different between the non-DR and DR groups, and 13 out of 20 factors
54
55 were found to be different between the non-STDR and STDR groups. Basically, all
56
57
58
59
60

1
2
3
4 risk factors were divided into non-modifiable and modifiable risk factors.
5
6 Non-modifiable factors included gender, age, diagnosis age, and diabetes duration. In
7
8 both the non-DR/ DR and the non-STDR/STDR analyses, gender showed no
9
10 significant differences. This was also reported in several previous studies ^{10,12}, while
11
12 the results of some studies remained controversial ^{11,13}. Significantly younger age was
13
14 observed in the DR and STDR groups, and a longer duration of diabetes was also
15
16 found in the DR and STDR groups. Longer duration may represent a longer period of
17
18 retinal toxicity induced by high glucose levels, which is believed to be associated with
19
20 both vascular and neural death in the retina³⁶. The existing studies show an older or
21
22 much younger age in the DR patients than in the non-DR patients ²⁶. In our study, an
23
24 older age seemed to be a protective variable for DR but was instead found to be a
25
26 variable for STDR, especially in DM patients older than 60. This means that even
27
28 though older age was associated with a lower incidence of DR, it is associated with a
29
30 greater threat to vision. We thought that this phenomenon might be explained by the
31
32 higher mortality risk in older DR populations. However, as DR was correlated with
33
34 severe general diseases³⁷, this result might be related to survival bias. However, older
35
36 age also implied a longer suffering of hyperglycaemia, which might be more vision
37
38 threatening. Furthermore, we explored the relationship between age and HbA1c,
39
40 diabetes duration, and the therapeutic regimen. The results indicated that with
41
42 increasing age, the diabetes duration increased, while the HbA1c and use of insulin
43
44 decreased. This implied that although the duration of diabetes increased, older people
45
46 had a better glucose management and required milder medicine. In this way, age was
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 determined to be a protective factor.

5
6 Modifiable risk factors included the obesity index, blood pressure, medicine, blood
7
8 glucose, renal function and blood lipid levels. Both DR and STDR showed a
9
10 significantly higher WHR, blood pressure, blood glucose level, LDL and a higher
11
12 incidence of insulin use than the non-DR and non-STDR groups. BUN was only
13
14 significantly higher in the DR group than the non-DR group, meanwhile Cr was only
15
16 significantly higher in the STDR than in the non-STDR group. WHR was thought to be
17
18 associated with DM³⁸ and was also thought to be a risk factor for severe DR in
19
20 women³⁹. Our study showed similar results in the univariate analysis. High blood
21
22 pressure indicated a significantly higher incidence of DR and STDR, while the effects
23
24 did not increase after a certain level. Blood glucose and LDL were significantly higher
25
26 in the DR and STDR groups than in the non-DR and non-STDR groups, while the
27
28 cholesterol level showed no significant difference, indicating that the DR and STDR
29
30 groups had poor management of blood glucose and LDL. BUN and Cr were both
31
32 common variables that reflected renal function, and our study indicated that DR and
33
34 STDR showed a higher level of renal injury than the non-DR and non-STDR groups.
35
36 The application of oral medicine or insulin was also reported to be a risk factor in the
37
38 former studies, perhaps because of the severity of the disease condition¹¹.

39
40
41 Second, the results of multiple logistic regression analyses showed that independent
42
43 risk factors of DR and STDR were similar in the eight-factor analysis (with the
44
45 diagnosis age excluded) and were different in the all-factor analysis (with diagnosis
46
47 age, waistline, and hipline excluded). In the all-factor analysis, younger age, diabetes
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 duration and SBP were found to be independent risk factors for both DR and STDR,
4
5 while PBG, HbA1c, Triglyceride and LDL were found to be independent risk factors for
6
7 DR only, and FBG was found to be an independent risk factor for STDR only. Age,
8
9 diabetes duration and SBP were reported to be independent risk factors for DR or DR
10
11 progression^{10,20,25}, while differences in the blood glucose were harder to explain.
12
13 HbA1c has been reported to be an independent risk factor in the development and
14
15 progression of DR in earlier studies^{18,21}, but there is little evidence on the role of PBG
16
17 in DR progression. HbA1c has long been considered to represent the management
18
19 condition of blood glucose, and bad glucose management is known to contribute to
20
21 the occurrence and progression of DR^{9,10,11}. PBG was reported to be abnormal in 31%
22
23 of DM patients whose FBG was normal⁴⁰, so it was considered to be an important
24
25 diagnostic factor for DM. PBG was shown to be more valuable in the prediction of
26
27 ischaemic and haemorrhagic stroke and cardiovascular disease mortality, while FBG
28
29 showed only weak predictive power^{41,42}. Therefore, we thought that it was reasonable
30
31 that PBG was a risk factor for severe complications of DM, such as DR. One possible
32
33 mechanism of PBG in the progression of DR might be that PBG reflects the capacity
34
35 of insulin secretion, the peak of which was shown to be delayed in type 2 DM⁴³. High
36
37 levels of PBG indicate that insulin secretion is relatively insufficient, which might result
38
39 in a blood glucose fluctuation after food intake and subsequent harm to the targeted
40
41 organs. Our study first found that FBG was an independent risk factor for STDR,
42
43 although we note that the OR was only 1.043 for a 1 unit increase in FBG and thus
44
45 has a limited power to predict the incidence of STDR. No existing studies previously
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 showed that FBG was an independent risk factor for DR, which might be caused by a
5
6 higher predictive value of HbA1c in these studies. Determining a possible mechanism
7
8 of FBG for STDR required further studies. LDL and triglyceride levels were also
9
10 independent risk factors for DR, which indicated that the management of blood lipids
11
12 is very important for DR prevention but was of limited relevance for STDR compared
13
14 with the other risk factors.
15
16

17
18 This study explored the risk factors of DR and STDR, which provided some insights
19
20 for the DR progression in Chinese population, and our findings could be applied
21
22 nationwide for further DR management. Our study also had some limitations. First,
23
24 owing to the limitations of the device and screening environment, several variables
25
26 were incomplete. If we meant to analyse all variables in this study, considerable data
27
28 would be abandoned, and the results of multivariate regression might be influenced.
29
30
31 Second, although we tried to balance patients from north and south and from urban
32
33 and rural areas, the patients enrolled in the final all-factor logistic regression were not
34
35 fully balanced because of the exclusion of missing data. Third, patients and screening
36
37 clinics were not collected via stratified sampling and therefore were not fully
38
39 representative of patients in mainland China. Fourth, our study design was
40
41 cross-sectional. Compared to cohort studies, cross-sectional studies provide weaker
42
43 evidence, and the results must be carefully explained. Fifth, the risk factors explored
44
45 in this study had been reported in previous studies, and further studies should thus
46
47 include more risk factors. More cohort studies focusing on several areas of China will
48
49 therefore be required to expand on these results.
50
51
52
53
54
55
56
57
58
59
60

Conclusions

Our study demonstrated that age, diabetes duration and SBP were independent risk factors for both DR and STDR. PBG, HbA1c, Triglyceride and LDL were independent risk factors for DR only, and FBG was an independent risk factor for STDR only. These results are similar to the results of existing studies and may provide some evidence for the clinical prevention of DR and STDR, especially as FBG, PBG, and HbA1c were all important predictors for the occurrence or progression of DR, requiring stricter glucose control. More DR screening and information collection are required, which may decrease the incidence of DR and improve clinical results.

Acknowledgements:

Ownership of the program:

Chinese Foundation for Lifeline Express and Lifeline Express Hong Kong Foundation.

Funding/Support:

This study was also supported by the Beijing Municipal Science & Technology Commission. Grant Number: Z141107002514042

Conflicts of interest: No potential conflicts of interest were reported.

Data sharing statement: No additional data are available.

Author Contributions: Y.L. and J.Y designed the whole study, completed the data collection, and wrote the manuscript. J.Y and L.T performed the data analysis, and L.T contributed to the epidemic portion of the manuscript. H.L. and X.J. contributed to the study design, and contributed to the writing of the manuscript. M.Z. assisted with the study design, data collection and contributed to the editing of the manuscript. X.L.

oversaw the study, gave advice on the study design, and revised the manuscript. X.L. was the guarantor of this study and had full access to all the data in this study. X.L. also takes responsibility for the integrity of the data and the accuracy of the data analysis.

Reference:

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. *Diabetes Care*. 1998; 21: 1414-31.
2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. *Lancet Glob Health*. 2013;1(6):e339–49
3. Jones S, Edwards R T. Diabetic retinopathy screening: a systematic review of the economic evidence. *Diabet Med*. 2010, 27(3):249–256.
4. Heintz, E., Wiréhn, A.B., Peebo, B.B., et al. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. *Diabetologia*. 53(10), 2147–2154 (2010)
5. Moriya T, Tanaka S, Sone H, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. *J Diabetes Complications*. 2016 Jun 29. pii: S1056-8727(16)30224-0.
6. de Moraes G1, Layton CJ. Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy. *Clin Experiment Ophthalmol*. 2016 Jun 23.
7. Lim Y, Chun S, Lee JH, et al. Association of bone mineral density and diabetic

1
2
3
4 retinopathy in diabetic subjects: the 2008-2011 Korea National Health and Nutrition
5
6 Examination Survey. *Osteoporos Int*. 2016 Jul;27(7):2249-57.

7
8
9 8.Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is
10
11 increased even with mild diabetic retinopathy: the Japan Diabetes Complications
12
13 Study. *Ophthalmology*. 2013;120(3):574–82.

14
15
16 9.Knudsen L L, Lervang H H, Lundbye-Christensen S, et al. The North Jutland County
17
18 Diabetic Retinopathy Study: population characteristics. *Br J Ophthalmol*. 2006,
19
20 90(11):1404-9.

21
22
23 10. Bertelsen G, Peto T, Lindekleiv H, et al. Tromsø eye study: prevalence and risk
24
25 factors of diabetic retinopathy. *Acta Ophthalmol*, 2013, 91(8):716-21.

26
27
28 11. Dr. Xinzhi Zhang, Dr. Jinan B. Saaddine, Dr. Chiu-Fang Chou, et al. Prevalence of
29
30 Diabetic Retinopathy in the United States, 2005–2008. *JAMA*. 2010, 304(6):649-656.

31
32
33 12. Piermarocchi R, Piermarocchi S, Tognetto D, et al. Prevalence of Diabetic
34
35 Retinopathy and Its Risk Factors in the PAMDI Population of the Mediterranean Basin.
36
37 *Eur J Ophthalmol*. 2015, 25(3).

38
39
40 13. George M, Harper R, Balamurugan A, et al. Diabetic retinopathy and its risk
41
42 factors in a population-based study. *J Prim Care Community Health*. 2011,
43
44 2(2):122-126.

45
46
47 14. Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM. Prevalence and
48
49 relationship between diabetic retinopathy and nephropathy, and its risk factors in the
50
51 North-East of Spain, a population-based study. *Ophthalmic Epidemiol*. 2010
52
53 Aug;17(4):251-65.

- 1
2
3
4 15. Dedov I, Maslova O, Suntssov Y, et al. Prevalence of diabetic retinopathy and
5
6 cataract in adult patients with type 1 and type 2 diabetes in Russia. *Rev Diabet Stud.*
7
8 2009, 6(2):124-9.
9
10
11 16. Pugliese G, Solini A, Zoppini G, et al. High prevalence of advanced retinopathy in
12
13 patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events
14
15 (RIACE) Italian Multicenter Study. *Diabetes Res Clin Pract.* 2012, 98(2):329–337.
16
17
18 17. Villena J E, Yoshiyama C A, Sánchez J E, et al. Prevalence of diabetic retinopathy
19
20 in Peruvian patients with type 2 diabetes: results of a hospital-based retinal
21
22 telescreening program. *Rev Panam Salud Publica.* 2011, 30(5):408-14.
23
24
25 18. Esteves J F, Kramer C K, Azevedo M J, et al. Prevalence of diabetic retinopathy in
26
27 patients with type 1 diabetes mellitus. *Rev Assoc Med Bras.* 2009, 55(3):268-73.
28
29
30 19. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, et al. Ten-year
31
32 incidence of diabetic retinopathy and macular edema. Risk factors in a sample of
33
34 people with type 1 diabetes. *Diabetes Res Clin Pract.* 2011, 94(1):126-32.
35
36
37 20. Kajiwara A, Miyagawa H, Saruwatari J, et al. Gender differences in the incidence
38
39 and progression of diabetic retinopathy among Japanese patients with type 2
40
41 diabetes mellitus: A clinic-based retrospective longitudinal study. *Diabetes Res Clin*
42
43 *Pract.* 2014, 103(3):7-10.
44
45
46 21. Tam V H, Lam E P, Chu B C, et al. Incidence and progression of diabetic
47
48 retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. *J Diabetes*
49
50 *Complications.* 2008, 23(3):185-93.
51
52
53 22. Henricsson M, Nyström L, Blohmé G, et al. The incidence of retinopathy 10 years
54
55
56
57
58
59
60

1
2
3
4 after diagnosis in young adult people with diabetes: results from the nationwide
5
6 population-based Diabetes Incidence Study in Sweden (DISS). *Diabetes Care*. 2003,
7
8 26(2):349-354.
9

10
11 23. Stratton I M, Kohner E M, Aldington S J, et al. UKPDS 50: Risk factors for
12
13 incidence and progression, of retinopathy in Type II diabetes over 6 years from
14
15 diagnosis. *Diabetologia*. 2001, 44(2):156-63.
16
17

18
19 24. Salinerofort M Á, Burgoslunar C D, Arrietablanco F J, et al. Four-Year Incidence of
20
21 Diabetic Retinopathy in a Spanish Cohort: The MADIABETES Study. *PLoS One*.
22
23 2012, 8(8):377-380.
24
25

26
27 25. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence
28
29 of diabetic retinopathy. The Beijing Eye Study 2001/2011. *PLoS One*.
30
31 2014;9(10):e1111320.
32
33

34
35 26. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of
36
37 diabetic retinopathy during 17 years of a population-based screening program in
38
39 England. *Diabetes Care*. 2012;35(3):592-6.
40

41
42 27. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS
43
44 report number 12. Early Treatment Diabetic Retinopathy Study Research Group.
45
46 *Ophthalmology*. 1991;98(5 Suppl):823-33.
47

48
49 28. Yan ZP, Ma JX. Risk factors for diabetic retinopathy in northern Chinese patients
50
51 with type 2 diabetes mellitus. *Int J Ophthalmol*. 2016 Aug 18;9(8):1194-9.
52

53
54 29. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic
55
56 macular edema and related vision loss. *Eye Vis (Lond)*. 2015 Sep 30;2:17.
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Zhou M, Astell-Burt T, Bi Y, et al. Geographical variation in diabetes prevalence and detection in china: multilevel spatial analysis of 98,058 adults. *Diabetes Care*. 2015;38(1):72-81.
31. Liu Y, Song Y, Tao L, et al. Prevalence of diabeticretinopathy among 13473patients with diabetesmellitus in China: a cross sectionalepidemiologicalsurvey in six provinces. *BMJOpen* 2017;7:e013199.
32. Harding S, Greenwood R, Aldington S, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. *Diabet Med*. 2003;20(12):965-971.
33. BCGuidelines.ca: Hypertension – Diagnosis and Management (2015). Available at: www.bcguidelines.ca
34. Mansfield ER, Helms BP. Detecting multicollinearity. *Am Stat*. 1982;36(3):158–60.
35. Semeraro F, Parrinello G, Cancarini A, Pasquini L, Zarra E, Cimino A, Cancarini G, Valentini U, Costagliola C. Predicting the risk of diabetic retinopathy in type 2 diabetic patients. *J Diabetes Complications*. 2011 Sep-Oct;25(5):292-7.
36. Nakamura M, Barber AJ, Antonetti DA, LaNoue KF, Robinson KA, et al. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. *J Biol Chem*. 2011;276: 43748–43755
37. Juutilainen A, Lehto S, Ronnema T, Pyorala K, Laakso M: Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. *Diabetes Care*. 2007;30:292–299.
38. Fauziana R, Jeyagurunathan A, Abdin E. Body mass index, waist-hip ratio and

1
2
3
4 risk of chronic medical condition in the elderly population: results from the Well-being
5
6 of the Singapore Elderly (WiSE) Study. *BMC Geriatr.* 2016 Jun 18;16(1):125.
7

8
9 39. Man RE1, Sabanayagam C2, Chiang PP. Differential Association of Generalized
10
11 and Abdominal Obesity With Diabetic Retinopathy in Asian Patients With Type 2
12
13 Diabetes. *JAMA Ophthalmol.* 2016 Mar 1;134(3):251-7.
14

15
16 40. Eriksson J, Jousilahti P, Lindström J, et al. Is fasting glucose sufficient to define
17
18 diabetes? Epidemiological data from 20 European studies. *Diabetologia,*
19
20 1999;Jun;42(6):647-54.
21

22
23 41. Hyvärinen M, Tuomilehto J, Mähönen M. Hyperglycemia and incidence of
24
25 ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose
26
27 criteria. *Stroke.* 2009 May;40(5):1633-7.
28

29
30 42. Ning F1, Tuomilehto J, Pyörälä K. Cardiovascular disease mortality in Europeans
31
32 in relation to fasting and 2-h plasma glucose levels within a normoglycemic range.
33
34 *Diabetes Care.* 2010 Oct;33(10):2211-6.
35

36
37 43. Guillausseau PJ, Meas T, Virally M. Abnormalities in insulin secretion in type 2
38
39 diabetes mellitus. *Diabetes Metab.* 2008 Feb;34 Suppl 2:S43-8.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends.

Figure 1 Flow diagram of the data processing.

Figure 2 Nomograms for DR (A) and STDR (B) risk factors. Risk factors were chosen based on results of logistic regression analysis. Each risk factor of the patient was assessed on basis of the nomogram and got a point by vertically corresponding to the first line Aggregated points of each risk factor corresponded to a particular occurrence probability of DR or STDR in the last line.

Table 1—Univariate analysis of DR risk factors. (N=12733)

Variable	n	No DR (n=8772)	n	DR (n=3961)	P	OR	95%CI
Male gender, n(%)	8772	3985(45.4%)	3961	1851(46.7%)	0.172		
Age, years(SD)	8770	63.0(10.3)	3959	61.0(9.8)	<0.001		
<30, %	11	30.6%	25	69.4%			
30-40, % (vs.<30)	143	66.8%	71	33.2%	0.757	1.128	0.526-2.423
40-50, % (vs.30-40)	733	64.2%	408	35.8%	0.469	1.121	0.823-1.527
50-60, % (vs.40-50)	2138	63.2%	1243	36.8%	0.542	1.004	0.908-1.201
60-70, % (vs.50-60)	3443	69.7%	1494	30.3%	<0.001	0.746	0.680-0.819
>70, % (vs.60-70)	2217	76.0%	700	24.0%	<0.001	0.728	0.655-0.808
Diagnosis age, years (SD)	8770	56.3 (10.2)	3959	50.8 (10.3)	<0.001		
Diabetes duration, years (SD)	8772	6.7 (5.9)	3961	10.2 (6.8)	<0.001		
<5, %	4692	80.0%	1174	20.0%			
5-10, % (vs. <5)	2314	65.7%	1208	34.3%	<0.001	2.086	1.898-2.293
10-15, % (vs. 5-10)	1032	57.6%	761	42.4%	<0.001	1.413	1.257-1.587
15-20, % (vs. 10-15)	521	48.2%	560	51.8%	<0.001	1.458	1.252-1.696
>20, % (vs. 15-20)	213	45.2%	258	54.8%	0.281	1.127	0.907-1.400
BMI (SD)	6000	24.7 (3.5)	2854	24.9 (3.9)	0.116		
Underweight, %	97	64.7%	53	35.3%			
Normal weight, % (vs. underweight)	3348	68.5%	1543	31.5%	0.326	0.843	0.600-1.185
Overweight, % (vs. normal weight)	2175	67.6%	1043	32.4%	0.414	1.041	0.946-1.145
Obese, % (vs. overweight)	380	63.9%	215	36.1%	0.076	1.180	0.983-1.417
SBP, mmHg (SD)	8762	133.3 (16.5)	3952	137.0(17.9)	<0.001		
DBP, mmHg (SD)	8762	79.6 (9.9)	3952	80.8 (10.8)	<0.001		
Normal BP, %	5084	72.3%	1950	27.7%			
BP level 1, % (vs. normal)	2840	66.7%	1420	33.3%	<0.001	1.303	1.200-1.414
BP level 2, % (vs. level 1)	665	59.3%	456	40.7%	<0.001	1.371	1.198-1.569
BP level 3, % (vs. level 2)	173	57.9%	126	42.1%	0.648	1.062	0.820-1.376
Waistline, cm (SD)	5719	89.3 (10.1)	2735	90.3 (10.6)	<0.001		
Hipline, cm (SD)	5719	96.6 (9.7)	2735	97.1 (9.5)	0.028		
WHR (SD)	5719	0.926 (0.074)	2735	0.930 (0.069)	0.007		
Abdominal obesity, n(%)		4677 (81.8%)		2267 (82.9%)	0.213	1.079	0.957-1.217
Female (SD)	3152	0.915 (0.076)	1501	0.923 (0.072)	0.002		
Male (SD)	2567	0.94 (0.070)	1234	0.94 (0.064)	0.674		
Medicine	5793		2797		<0.001		

No medicine, %	660	87.0%	99	13.0%			
Oral medicine, % (vs. no medicine)	3296	73.2%	1208	26.8%	<0.001	5.407	4.331-6.752
Insulin, % (vs. oral medicine)	1837	55.2%	1490	44.8%	<0.001	2.213	2.013-2.434
FBG, mmol/L (SD)	7547	7.8 (2.4)	3517	8.7 (3.0)	<0.001		
PBG, mmol/L (SD)	4780	10.7 (3.3)	2095	11.8 (3.5)	<0.001		
HbA1c, % (SD)	7762	7.16 (1.65)	3146	7.82 (1.90)	<0.001		
BUN, mmol/L (SD)	6357	5.79 (8.19)	2633	6.33 (10.51)	0.01		
Cr, μ mol/L (SD)	6320	76.5 (112.7)	2615	78.8 (39.2)	0.328		
Cholesterol, mmol/L (SD)	6418	5.04 (2.69)	2651	5.06 (1.31)	0.752		
Triglyceride, mmol/L (SD)	6382	1.87 (1.22)	2635	1.89 (1.26)	0.456		
HDL, mmol/L (SD)	6392	1.37 (0.56)	2642	1.38 (0.57)	0.481		
LDL, mmol/L (SD)	6399	2.72 (1.00)	2643	2.83 (1.00)	<0.001		

Continuous variables were reported as mean value and standard deviation, and categorical variables were reported as percentage, OR and 95% CI. P<0.05 was considered statistically significant and marked in bold. n, number; OR, odd ratio; 95%CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist hip ratio; FBG, fasting blood glucose; PBG, postprandial blood glucose; HbA1c, glycosylated hemoglobin; BUN, blood urea nitrogen; Cr, creatinine; HDL, high density lipoprotein; LDL, low density lipoprotein.

Table 2—Univariate analysis of STDR risk factors. (N=12621)

Variable	n	None-STDR (n=10875)	n	STDR (n=1746)	P	OR	95%CI
Male gender, n(%)	10875	4985 (45.8%)	1746	799 (45.8%)	0.952		
Age, years (SD)	10873	62.7 (10.2)	1745	60.4 (9.7)	<0.001		
<30, %	32	88.9%	4	11.1%			
30-40, % (vs.<30)	181	85.0%	32	15.0%	0.757	1.128	0.526-2.423
40-50, % (vs.30-40)	927	81.9%	205	18.1%	0.469	1.121	0.823-1.527
50-60, % (vs.40-50)	2785	82.9%	576	17.1%	0.542	1.004	0.908-1.201
60-70, % (vs.50-60)	4253	86.9%	643	13.1%	<0.001	0.746	0.680-0.819
>70, % (vs.60-70)	2160	88.9%	270	11.1%	<0.001	0.728	0.655-0.808
Diagnosis age, years (SD)	10873	55.4 (10.4)	1745	49.4 (10.4)	<0.001		
Diabetes duration, years (SD)	10875	7.2 (6.2)	1746	11.0 (6.8)	<0.001		
<5, %	4692	80.0%	1174	20.0%			
5-10, % (vs. <5)	2314	65.7%	1208	34.3%	<0.001	2.086	1.898-2.293
10-15, % (vs. 5-10)	1032	57.6%	761	42.4%	<0.001	1.413	1.257-1.587
15-20, % (vs. 10-15)	521	48.2%	560	51.8%	<0.001	1.458	1.252-1.696
>20, % (vs. 15-20)	213	45.2%	258	54.8%	0.281	1.127	0.907-1.400
BMI (SD)	7518	24.8 (3.6)	1256	24.8 (3.9)	0.738		
Underweight	120	81.1%	28	18.9%			
Normal weight, % (vs. underweight)	4145	85.5%	703	14.5%	0.134	0.727	0.478-1.105
Overweight, % (vs. normal weight)	2759	86.6%	428	13.4%	0.177	0.915	0.804-1.041
Obese, % (vs. overweight)	494	83.6%	97	16.4%	0.054	1.266	0.995-1.610
SBP, mmHg (SD)	10863	133.8 (16.7)	1741	138.1 (18.7)	<0.001		
DBP, mmHg (SD)	10863	79.8 (10.0)	1741	81.0 (11.4)	<0.001		
Normal BP, %	6164	88.2%	826	11.8%			
BP level 1, % (vs. normal BP)	3584	85.0%	630	15.0%	<0.001	1.312	1.173-1.467
BP level 2, % (vs. BP level 1)	892	80.5%	216	19.5%	<0.001	1.378	1.161-1.635
BP level 3, % (vs. BP level 2)	223	76.4%	69	23.6%	0.118	1.278	0.939-1.739
Waistline, cm(SD)	7176	89.4 (10.1)	1200	90.7 (10.8)	<0.001		
Hipline, cm(SD)	7176	96.7 (9.6)	1200	97.2 (10.1)	0.120		
WHR (SD)	7176	0.926 (0.073)	1200	0.934(0.071)	0.001		
Abdominal obesity,n(%)		5872(81.8%)		1004(83.7%)	0.124	1.113	0.970-1.276
Female (SD)	3947	0.92 (0.075)	666	0.93 (0.074)	<0.001		

1								
2								
3	Male (SD)	3229	0.94 (0.069)	534	0.94 (0.065)	0.634		
4	Medicine	7304		1218		<0.001		
5	No medicine, %	727	93.7%	49	6.3%			
6	Oral medicine, %	4008	89.6%	465	10.4%	<0.001	2.908	1.982-4.267
7	(vs. no medicine)							
8	Insulin, %	2569	78.0%	724	22.0%	<0.001	2.429	2.140-2.757
9	(vs. oral medicine)							
10	FBG, mmol/L (SD)	9451	8.0 (2.5)	1521	8.9 (3.1)	<0.001		
11	PBG, mmol/L (SD)	5964	10.9 (3.3)	886	11.9 (3.6)	<0.001		
12	HbA1c, % (SD)	9548	7.25 (1.70)	1280	8.05 (1.97)	<0.001		
13	BUN, mmol/L (SD)	7855	5.89 (9.38)	1072	6.38 (4.99)	0.092		
14	Cr, µmol/L (SD)	7812	76.2 (102.1)	1060	84.2 (52.3)	0.012		
15	Cholesterol, mmol/L (SD)	7927	5.05 (2.48)	1079	5.06 (1.29)	0.904		
16	Triglyceride, mmol/L (SD)	7884	1.87 (1.22)	1072	1.94 (1.29)	0.072		
17	HDL, mmol/L (SD)	7897	1.37 (0.56)	1074	1.38 (0.54)	0.755		
18	LDL, mmol/L (SD)	7907	2.74 (0.99)	1072	2.82 (1.06)	0.015		

P<0.05 was considered statistically significant and marked in bold.

Table 3 —Logistic regression of DR and STDR risk factors. (Both in eight-factor analysis and all-factor analysis.)

Variable	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p	OR	95% CI	p
	DR risk factors analysis						STDR risk factors analysis					
	eight-factor analysis (N=9367)			all-factor analysis (N=4623)			eight-factor analysis (N=9303)			all-factor analysis (N=4597)		
Sex (women vs men)	1.026	0.932-1.130	0.169	1.052	0.913-1.213	0.489	0.979	0.855-1.120	0.753	1.176	0.960-1.442	0.118
Age	0.966	0.961-0.971	<0.001	0.968	0.961-0.976	<0.001	0.961	0.954-0.968	<0.001	0.961	0.950-0.972	<0.001
Diabetes duration	1.102	1.093-1.111	<0.001	1.071	1.059-1.084	<0.001	1.102	1.091-1.113	<0.001	1.077	1.061-1.094	<0.001
SBP	1.015	1.011-1.018	<0.001	1.016	1.010-1.021	<0.001	1.017	1.011-1.021	<0.001	1.017	1.010-1.024	<0.001
DBP	0.995	0.989-1.001	0.083	0.994	0.986-1.002	0.152	0.987	0.980-0.995	0.002	0.990	0.979-1.002	0.095
FBG	1.040	1.019-1.062	<0.001	1.008	0.972-1.046	0.666	1.043	1.016-1.071	0.002	1.076	1.028-1.127	0.002
HbA1c	1.164	1.128-1.201	<0.001	1.102	1.051-1.156	<0.001	1.168	1.172-1.250	<0.001	1.060	0.994-1.130	0.077
PBG				1.039	1.014-1.065	0.003				1.013	0.979-1.048	0.473
BMI				0.991	0.972-1.012	0.406				0.976	0.948-1.005	0.109
WHR				1.527	0.591-3.947	0.382				3.314	0.927-11.842	0.065
Medicine												
Oral vs. no medicine				2.158	1.517-3.069	<0.001				3.737	1.721-8.113	0.001
Insulin vs. no medicine				3.535	2.455-5.089	<0.001				6.856	3.141-14.966	<0.001
BUN				1.004	0.997-1.011	0.238				1.002	0.994-1.010	0.598
Cr				1.000	1.000-1.001	0.745				1.000	1.000-1.001	0.121
Cholesterol				0.999	0.955-1.044	0.948				0.995	0.924-1.071	0.890
Triglyceride				0.924	0.873-0.979	0.007				0.950	0.878-1.028	0.200

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

HDL	1.030	0.901-1.176	0.668	0.970	0.789-1.193	0.776
LDL	1.099	1.017-1.187	0.017	1.093	0.978-1.221	0.118

P<0.05 was considered statistically significant and marked in bold.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram of the data processing.

163x151mm (300 x 300 DPI)

only




Figure 2 Nomograms for DR (A) and STDR (B) risk factors.

Risk factors were chosen based on results of logistic regression analysis. Each risk factor of the patient was assessed on basis of the nomogram and got a point by vertically corresponding to the first line Aggregated points of each risk factor corresponded to a particular occurrence probability of DR or STDR in the last line.

172x85mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4, 5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9-10
		(c) Consider use of a flow diagram	Separately uploaded
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	25-26
		(b) Indicate number of participants with missing data for each variable of interest	25-26
Outcome data	15*	Report numbers of outcome events or summary measures	25-26
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	25-26
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-12 (DR analysis &STDR analysis)
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>